# EDGAR Filing Document

**Accession Number:** 0001827090
**File Stem:** 0001827090-25-000048
**Filing Date:** 2025-11
**Character Count:** 182088
**Document Hash:** 28bc4030fd4661aa891b94e431abc9dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001827090-25-000048.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001827090-25-000048

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 82

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Certara, Inc.
- **CENTRAL INDEX KEY:** 0001827090
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39799
- **FILM NUMBER:** 251458979

**BUSINESS ADDRESS:**
- **STREET 1:** 4 RADNOR CORPORATE CENTER, SUITE 350
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (415) 237-8272

**MAIL ADDRESS:**
- **STREET 1:** 4 RADNOR CORPORATE CENTER, SUITE 350
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087

?xml version='1.0' encoding='ASCII'? cert-20250930

<u>[**Table of Contents**](#if278e3577cb24443aabadc27af2f7e0f_13)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_________________________

**FORM 10-Q**

_________________________

---

| | |
|:---|:---|
| **(Mark One)** | **(Mark One)** |
| ⌧ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES** |
| **EXCHANGE ACT OF 1934** | **EXCHANGE ACT OF 1934** |

---

**For the quarterly period ended September 30, 2025** 

**or**

---

| | |
|:---|:---|
| □ | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES** |
| **EXCHANGE ACT OF 1934** | **EXCHANGE ACT OF 1934** |

---

**For the transition period from ______________ to ______________**

**Commission File Number: 001-39799**

_________________________

**Certara, Inc.**

**(Exact name of registrant as specified in its charter)**

_________________________

---

| | |
|:---|:---|
| **Delaware** | 82-2180925 |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification Number)** |

---

**4 Radnor Corporate Center**

**Suite 350**

**Radnor, Pennsylvania 19087**

**(Address of Principal Executive Offices)**

**(415) 237-8272**

**(Registrant's telephone number)**

_________________________

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol** | **Name of Exchange on which registered** |
| **Common stock, par value $0.01 per share** | **CERT** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

------

<u>[**Table of Contents**](#if278e3577cb24443aabadc27af2f7e0f_13)</u>

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | □ | | |
| Non-accelerated filer | □ | Smaller reporting company | □ | Emerging growth company | □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ⌧

As of November 1, 2025, the registrant had 159,273,367 shares of common stock, par value $0.01 per share, outstanding.

------

<u>[**Table of Contents**](#if278e3577cb24443aabadc27af2f7e0f_13)</u>

**Certara, Inc.**

Unless otherwise indicated, references to the "Company," "Certara," "we," "us," and "our" refer to Certara, Inc. and its consolidated subsidiaries.

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

&nbsp;&nbsp;&nbsp;&nbsp;• any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to compete within our market;

&nbsp;&nbsp;&nbsp;&nbsp;• changes or delays in government regulation relating to the biopharmaceutical industry;

&nbsp;&nbsp;&nbsp;&nbsp;• trends in research and development ("R&D") spending, the use of third parties by biopharmaceutical companies and a shift toward more R&D occurring at smaller biotechnology companies;

&nbsp;&nbsp;&nbsp;&nbsp;• consolidation within the biopharmaceutical industry;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully increase our customer base, expand our relationships and the products and services we provide, and enter new markets;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to retain key personnel or recruit additional qualified personnel;

&nbsp;&nbsp;&nbsp;&nbsp;• risks related to the mischaracterization of our independent contractors;

&nbsp;&nbsp;&nbsp;&nbsp;• any delays or defects in our release of new or enhanced software or other biosimulation tools;

&nbsp;&nbsp;&nbsp;&nbsp;• issues relating to the use of artificial intelligence and machine learning in our products and services;

&nbsp;&nbsp;&nbsp;&nbsp;• failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by our existing customers;

&nbsp;&nbsp;&nbsp;&nbsp;• risks related to our contracts with government customers, including the ability of third parties to challenge our receipt of such contracts;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to sustain historic growth rates;

&nbsp;&nbsp;&nbsp;&nbsp;• any future acquisitions and our ability to successfully integrate such acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;• the accuracy of our addressable market estimates;

------

<u>[**Table of Contents**](#if278e3577cb24443aabadc27af2f7e0f_13)</u>

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully operate a global business;

&nbsp;&nbsp;&nbsp;&nbsp;• adverse global economic conditions, including inflation, tariffs and/or trade disputes and fluctuating interest rates;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to comply with applicable anti-corruption, trade compliance and economic sanctions laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;• risks related to litigation against us;

&nbsp;&nbsp;&nbsp;&nbsp;• the adequacy of our insurance coverage and our ability to obtain adequate insurance coverage in the future;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to perform our services in accordance with contractual requirements, regulatory standards and ethical considerations;

&nbsp;&nbsp;&nbsp;&nbsp;• the loss of more than one of our major customers;

&nbsp;&nbsp;&nbsp;&nbsp;• the ability or inability of our bookings to accurately predict our future revenue and our ability to realize the anticipated revenue reflected in our bookings;

&nbsp;&nbsp;&nbsp;&nbsp;• any disruption in the operations of the third-party providers who host our software solutions or any limitations on their capacity or interference with our use;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to reliably meet our data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet;

&nbsp;&nbsp;&nbsp;&nbsp;• any unauthorized access to or use of customer or other proprietary or confidential data or other breach of our cybersecurity measures;

&nbsp;&nbsp;&nbsp;&nbsp;• the occurrence of natural disasters, pandemics, epidemic diseases, and public health crises, which may result in delays or cancellations of customer contracts or decreased utilization by our employees;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to comply with the terms of any licenses governing our use of third-party open source software utilized in our software solutions;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to comply with applicable privacy and cybersecurity laws;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to adequately enforce or defend our ownership and use of our intellectual property and other proprietary rights;

&nbsp;&nbsp;&nbsp;&nbsp;• any allegations that we are infringing, misappropriating or otherwise violating a third party's intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;• our ability to meet the obligations under our current or future indebtedness as they become due;

&nbsp;&nbsp;&nbsp;&nbsp;• any limitations on our ability to pursue our business strategies due to restrictions under our current or future indebtedness or inability to comply with any restrictions under such indebtedness;

&nbsp;&nbsp;&nbsp;&nbsp;• any impairment of goodwill or other intangible assets;

&nbsp;&nbsp;&nbsp;&nbsp;• the accuracy of our estimates and judgments relating to our critical accounting policies and any changes in financial reporting standards or interpretations;

&nbsp;&nbsp;&nbsp;&nbsp;• any inability to design, implement, and maintain effective internal controls when required by law, or inability to timely remediate internal controls that are deemed ineffective; and

&nbsp;&nbsp;&nbsp;&nbsp;• the other factors described elsewhere in this Quarterly Report, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 ("2024 Annual Report"), and in the other documents and reports we file with the Securities and Exchange Commission (the "SEC").

------

<u>[**Table of Contents**](#if278e3577cb24443aabadc27af2f7e0f_13)</u>

You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements in this Quarterly Report are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. There are important factors, including those described in this Quarterly Report, in the section titled "Risk Factors" in our most recent Annual Report, and in our subsequent SEC filings, which could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements.

The forward-looking statements made in this Quarterly Report relate only to events as of the date on which the statements are made. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations.

**Channels for Disclosure of Information**

Investors and others should note that we may announce material information to the public through filings with the SEC, our Investors Relations website (https://ir.certara.com), press releases, public conference calls and public webcasts. We use these channels to communicate with the public about the Company, our products, our services and other matters. We have used, and intend to continue to use, our Investor Relations website and our corporate website located at www.certara.com as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. We encourage our investors, the media and others to review the information disclosed through these channels as such information could be deemed to be material information. The information on or available through such channels, including on our website, is not incorporated by reference in this Quarterly Report and shall not be deemed to be incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. This list of disclosure channels may be updated from time to time.

------

<u>[**Table of Contents**](#if278e3577cb24443aabadc27af2f7e0f_13)</u>

**CERTARA, INC. AND SUBSIDIARIES**

**FORM 10-Q**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **Item** | | **Page** |
| | **[PART I – FINANCIAL INFORMATION](#if278e3577cb24443aabadc27af2f7e0f_16)** | |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[1.](#if278e3577cb24443aabadc27af2f7e0f_19)</u> | <u>[Financial Statements (Unaudited)](#if278e3577cb24443aabadc27af2f7e0f_19)</u> | [7](#if278e3577cb24443aabadc27af2f7e0f_19) |
|  | <u>[Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024](#if278e3577cb24443aabadc27af2f7e0f_22)</u> | [7](#if278e3577cb24443aabadc27af2f7e0f_22) |
|  | <u>[Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2025 and 2024](#if278e3577cb24443aabadc27af2f7e0f_25)</u> | [8](#if278e3577cb24443aabadc27af2f7e0f_25) |
|  | <u>[Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024](#if278e3577cb24443aabadc27af2f7e0f_28)</u> | [9](#if278e3577cb24443aabadc27af2f7e0f_28) |
|  | <u>[Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024](#if278e3577cb24443aabadc27af2f7e0f_34)</u> | [11](#if278e3577cb24443aabadc27af2f7e0f_34) |
|  | <u>[Notes to Condensed Consolidated Financial Statements](#if278e3577cb24443aabadc27af2f7e0f_37)</u> | [12](#if278e3577cb24443aabadc27af2f7e0f_37) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[2.](#if278e3577cb24443aabadc27af2f7e0f_85)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#if278e3577cb24443aabadc27af2f7e0f_85)</u> | [33](#if278e3577cb24443aabadc27af2f7e0f_85) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[3.](#if278e3577cb24443aabadc27af2f7e0f_121)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#if278e3577cb24443aabadc27af2f7e0f_121)</u> | [54](#if278e3577cb24443aabadc27af2f7e0f_121) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[4.](#if278e3577cb24443aabadc27af2f7e0f_124)</u> | <u>[Controls and Procedures](#if278e3577cb24443aabadc27af2f7e0f_124)</u> | [54](#if278e3577cb24443aabadc27af2f7e0f_124) |
|  | **[PART II – OTHER INFORMATION](#if278e3577cb24443aabadc27af2f7e0f_127)** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[1.](#if278e3577cb24443aabadc27af2f7e0f_130)</u> | <u>[Legal Proceedings](#if278e3577cb24443aabadc27af2f7e0f_130)</u> | [55](#if278e3577cb24443aabadc27af2f7e0f_130) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[1A.](#if278e3577cb24443aabadc27af2f7e0f_133)</u> | <u>[Risk Factors](#if278e3577cb24443aabadc27af2f7e0f_133)</u> | [55](#if278e3577cb24443aabadc27af2f7e0f_133) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[2](#if278e3577cb24443aabadc27af2f7e0f_136)</u>. | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#if278e3577cb24443aabadc27af2f7e0f_136)</u> | [55](#if278e3577cb24443aabadc27af2f7e0f_136) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[3.](#if278e3577cb24443aabadc27af2f7e0f_139)</u> | <u>[Defaults Upon Senior Securities](#if278e3577cb24443aabadc27af2f7e0f_139)</u> | [55](#if278e3577cb24443aabadc27af2f7e0f_139) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[4.](#if278e3577cb24443aabadc27af2f7e0f_142)</u> | <u>[Mine Safety Disclosures](#if278e3577cb24443aabadc27af2f7e0f_142)</u> | [55](#if278e3577cb24443aabadc27af2f7e0f_142) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[5.](#if278e3577cb24443aabadc27af2f7e0f_145)</u> | <u>[Other Information](#if278e3577cb24443aabadc27af2f7e0f_145)</u> | [56](#if278e3577cb24443aabadc27af2f7e0f_145) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[6.](#if278e3577cb24443aabadc27af2f7e0f_151)</u> | <u>[Exhibits](#if278e3577cb24443aabadc27af2f7e0f_151)</u> | [56](#if278e3577cb24443aabadc27af2f7e0f_151) |
| <u>[SIGNATURES](#if278e3577cb24443aabadc27af2f7e0f_154)</u> | <u>[SIGNATURES](#if278e3577cb24443aabadc27af2f7e0f_154)</u> | [58](#if278e3577cb24443aabadc27af2f7e0f_154) |

---

------

<u>[**Table of Contents**](#if278e3577cb24443aabadc27af2f7e0f_13)</u>

**PART I — FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**CERTARA, INC. AND SUBSIDIARIES <br>CONDENSED CONSOLIDATED BALANCE SHEETS <br>(UNAUDITED)**

---

| | | |
|:---|:---|:---|
| **(IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA)** | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $172711 | $179183 |
| &nbsp;&nbsp;Accounts receivable, net of allowance for credit losses of $1,937 and $2,164, respectively | 89051 | 102189 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 21541 | 29480 |
| &nbsp;&nbsp;&nbsp;Total current assets | 283303 | 310852 |
| Other assets: |  |  |
| &nbsp;&nbsp;Property and equipment, net | 1846 | 2167 |
| &nbsp;&nbsp;Operating lease right-of-use assets | 12371 | 13841 |
| &nbsp;&nbsp;Goodwill | 773036 | 757038 |
| &nbsp;&nbsp;Intangible assets, net of accumulated amortization of $396,928 and $338,809, respectively | 459543 | 485214 |
| &nbsp;&nbsp;Deferred income taxes | 3961 | 3961 |
| &nbsp;&nbsp;Other long-term assets | 1796 | 2031 |
| &nbsp;&nbsp;&nbsp;Total assets | $1535856 | $1575104 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable | $3457 | $3502 |
| &nbsp;&nbsp;Accrued expenses | 59865 | 56451 |
| &nbsp;&nbsp;Current portion of deferred revenue | 65023 | 77829 |
| &nbsp;&nbsp;Current portion of long-term debt | 3000 | 3000 |
| &nbsp;&nbsp;Other current liabilities | 4175 | 5306 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 135520 | 146088 |
| Long-term liabilities: |  |  |
| &nbsp;&nbsp;Deferred revenue, net of current portion | 857 | 1049 |
| &nbsp;&nbsp;Deferred income taxes | 30848 | 40421 |
| &nbsp;&nbsp;Operating lease liabilities, net of current portion | 8965 | 11166 |
| &nbsp;&nbsp;Long-term debt, net of current portion and debt discount | 290541 | 292425 |
| &nbsp;&nbsp;Other long-term liabilities | 4318 | 25299 |
| &nbsp;&nbsp;&nbsp;Total liabilities | 471049 | 516448 |
| Commitments and contingencies (refer to note 10) |  |  |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;Preferred shares, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;Common shares, $0.01 par value, 600,000,000 shares authorized, 163,873,911 and 161,958,810 shares issued, 159,396,847 and 161,009,112 shares outstanding as of September 30, 2025 and December 31, 2024, respectively | 1640 | 1620 |
| &nbsp;&nbsp;Additional paid-in capital | 1247464 | 1216925 |
| &nbsp;&nbsp;Accumulated deficit | (123981) | (128281) |
| &nbsp;&nbsp;Accumulated other comprehensive income (loss) | 1947 | (13424) |
| &nbsp;&nbsp;Treasury stock at cost, 4,477,064 and 949,698 shares at September 30, 2025 and December 31, 2024, respectively | (62263) | (18184) |
| &nbsp;&nbsp;&nbsp;Total stockholders' equity | 1064807 | 1058656 |
| &nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1535856 | $1575104 |

---

The accompanying notes are an integral part of the condensed consolidated financial statements.

------

<u>[**Table of Contents**](#if278e3577cb24443aabadc27af2f7e0f_13)</u>

**CERTARA, INC. AND SUBSIDIARIES** <br>**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** <br>**AND COMPREHENSIVE INCOME (LOSS)**<br>**(UNAUDITED)**<br>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** |
|<br>**(IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA)** | **2025** | **2024** | **2025** | **2024** |
| Revenues | $104616 | $94820 | $315190 | $284787 |
| Cost of revenues | 39718 | 37189 | 121955 | 116253 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;Sales and marketing | 12998 | 11347 | 39704 | 34247 |
| &nbsp;&nbsp;Research and development | 10266 | 8271 | 29760 | 29333 |
| &nbsp;&nbsp;General and administrative | 24647 | 22030 | 61487 | 73080 |
| &nbsp;&nbsp;Depreciation and amortization | 13982 | 13389 | 42104 | 39608 |
| &nbsp;&nbsp;&nbsp;Total operating expenses | 61893 | 55037 | 173055 | 176268 |
| &nbsp;&nbsp;&nbsp;Income (loss) from operations | 3005 | 2594 | 20180 | (7734) |
| Other income (expenses): |  |  |  |  |
| &nbsp;&nbsp;Interest expense | (5011) | (5187) | (14619) | (16516) |
| &nbsp;&nbsp;Net other income | 1739 | 932 | 4965 | 4886 |
| Total other expenses | (3272) | (4255) | (9654) | (11630) |
| &nbsp;&nbsp;Income (loss) before income taxes | (267) | (1661) | 10526 | (19364) |
| &nbsp;&nbsp;Provision (benefit) for income taxes | (1792) | (290) | 6226 | (736) |
| Net income (loss) attributable to common stockholders: | 1525 | (1371) | 4300 | (18628) |
| Other comprehensive income (loss): |  |  |  |  |
| &nbsp;&nbsp;Foreign currency translation adjustment, net of tax of $(144), $(390), $(1130), and $(346), respectively | (2418) | 5700 | 18957 | 4992 |
| &nbsp;&nbsp;Change in fair value from interest rate swap, net of tax of $(198), $(795), $(1222), and $(788), respectively | (584) | (2385) | (3586) | (2412) |
| &nbsp;&nbsp;&nbsp;Total other comprehensive income (loss) | (3002) | 3315 | 15371 | 2580 |
| Comprehensive income (loss) | $(1477) | $1944 | $19671 | $(16048) |
| Net income (loss) per share attributable to common stockholders: |  |  |  |  |
| &nbsp;&nbsp;Basic | $0.01 | $(0.01) | $0.03 | $(0.12) |
| &nbsp;&nbsp;Diluted | $0.01 | $(0.01) | $0.03 | $(0.12) |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;Basic | 160403011 | 160642052 | 160769603 | 160225375 |
| &nbsp;&nbsp;Diluted | 160600570 | 160642052 | 161263876 | 160225375 |

---

The accompanying notes are an integral part of the condensed consolidated financial statements.

------

**CERTARA, INC. AND SUBSIDIARIES <br>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY <br>(UNAUDITED)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **(IN THOUSANDS, <br>EXCEPT SHARE DATA)** | **COMMON STOCK** | **COMMON STOCK** | **ADDITIONAL<br>PAID-IN<br>CAPITAL** | **ACCUMULATED<br>DEFICIT** | **ACCUMULATED<br>OTHER <br>COMPREHENSIVE<br>INCOME** | **TREASURY STOCK** | **TREASURY STOCK** | **TOTAL<br>STOCKHOLDERS' <br>EQUITY** |
| **(IN THOUSANDS, <br>EXCEPT SHARE DATA)** | **SHARES** | **AMOUNT** | **ADDITIONAL<br>PAID-IN<br>CAPITAL** | **ACCUMULATED<br>DEFICIT** | **ACCUMULATED<br>OTHER <br>COMPREHENSIVE<br>INCOME** | **SHARES** | **AMOUNT** | **TOTAL<br>STOCKHOLDERS' <br>EQUITY** |
| Balance as of June 30, 2025 | 163856290 | 1639 | 1237891 | (125506) | 4949 | (3241400) | $(48394) | $1070579 |
| Equity-based compensation expense, net of forfeiture |  |  | 9574 |  |  |  |  | 9574 |
| Common stock withheld for tax liabilities |  |  |  |  |  | (5266) | (59) | (59) |
| Common shares issued for employee share-based compensation | 17621 | 1 | (1) |  |  |  |  |  |
| Common shares repurchased |  |  |  |  |  | (1230398) | (13810) | (13810) |
| Change in fair value from interest rate swap, net of tax |  |  |  |  | (584) |  |  | (584) |
| Net income |  |  |  | 1525 |  |  |  | 1525 |
| Foreign currency translation adjustment, net of tax |  |  |  |  | (2418) |  |  | (2418) |
| Balance as of September 30, 2025 | 163873911 | $1640 | $1247464 | $(123981) | $1947 | (4477064) | $(62263) | $1064807 |
| Balance as of December 31, 2024 | 161958810 | 1620 | 1216925 | (128281) | (13424) | (949698) | $(18184) | $1058656 |
| Equity-based compensation expense, net of forfeiture |  |  | 24889 |  |  |  |  | 24889 |
| Common stock withheld for tax liabilities |  |  |  |  |  | (503689) | (5019) | (5019) |
| Common shares issued for employee share-based compensation | 1459757 | 15 | (15) |  |  |  |  |  |
| Common shares issued for contingent consideration | 455344 | 5 | 5665 |  |  |  |  | 5670 |
| Common shares repurchased |  |  |  |  |  | (3023677) | (39060) | (39060) |
| Change in fair value from interest rate swap, net of tax |  |  |  |  | (3586) |  |  | (3586) |
| Net income |  |  |  | 4300 |  |  |  | 4300 |
| Foreign currency translation adjustment, net of tax |  |  |  |  | 18957 |  |  | 18957 |
| Balance as of September 30, 2025 | 163873911 | $1640 | $1247464 | $(123981) | $1947 | (4477064) | $(62263) | $1064807 |

---

The accompanying notes are an integral part of the condensed consolidated financial statements.

------

**CERTARA, INC. AND SUBSIDIARIES <br>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY <br>(UNAUDITED)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **(IN THOUSANDS, <br>EXCEPT SHARE DATA)** | **COMMON STOCK** | **COMMON STOCK** | **ADDITIONAL<br>PAID-IN<br>CAPITAL** | **ACCUMULATED<br>DEFICIT** | **ACCUMULATED<br>OTHER <br>COMPREHENSIVE<br>LOSS** | **TREASURY STOCK** | **TREASURY STOCK** | **TOTAL<br>STOCKHOLDERS' <br>EQUITY** |
| **(IN THOUSANDS, <br>EXCEPT SHARE DATA)** | **SHARES** | **AMOUNT** | **ADDITIONAL<br>PAID-IN<br>CAPITAL** | **ACCUMULATED<br>DEFICIT** | **ACCUMULATED<br>OTHER <br>COMPREHENSIVE<br>LOSS** | **SHARES** | **AMOUNT** | **TOTAL<br>STOCKHOLDERS' <br>EQUITY** |
| Balance as of June 30, 2024 | 161764197 | $1618 | $1201009 | $(133487) | $(8328) | (882883) | $(17411) | $1043401 |
| Equity-based compensation expense, net of forfeiture |  |  | 8187 |  |  |  |  | 8187 |
| Common stock withheld for tax liabilities |  |  |  |  |  | (8895) | (127) | (127) |
| Common shares issued for employee share-based compensation | 27792 |  |  |  |  |  |  |  |
| Change in fair value from interest rate swap, net of tax |  |  |  |  | (2385) |  |  | (2385) |
| Net loss |  |  |  | (1371) |  |  |  | (1371) |
| Foreign currency translation adjustment, net of tax |  |  |  |  | 5700 |  |  | 5700 |
| Balance as of September 30, 2024 | 161791989 | $1618 | $1209196 | $(134858) | $(5013) | (891778) | $(17538) | $1053405 |
| Balance as of December 31, 2023 | 160284901 | $1603 | $1178461 | $(116230) | $(7593) | (436615) | $(9401) | $1046840 |
| Equity-based compensation awards |  |  | 27043 |  |  |  |  | 27043 |
| Common stock withheld for tax liabilities |  |  |  |  |  | (455163) | (8137) | (8137) |
| Common shares issued for employee share-based compensation | 1297519 | 13 | (13) |  |  |  |  |  |
| Restricted stock forfeiture | (5123) |  |  |  |  |  |  |  |
| Common shares issued for contingent consideration | 214692 | 2 | 3705 |  |  |  |  | 3707 |
| Change in fair value from interest rate swap, net of tax |  |  |  |  | (2412) |  |  | (2412) |
| Net loss |  |  |  | (18628) |  |  |  | (18628) |
| Foreign currency translation adjustment, net of tax |  |  |  |  | 4992 |  |  | 4992 |
| Balance as of September 30, 2024 | 161791989 | $1618 | $1209196 | $(134858) | $(5013) | (891778) | $(17538) | $1053405 |

---

The accompanying notes are an integral part of the condensed consolidated financial statements.

------

**CERTARA, INC. AND SUBSIDIARIES <br>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS <br>(UNAUDITED)**

---

| | | |
|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** |
|<br>**(IN THOUSANDS)** | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net income (loss) | $4300 | $(18628) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 56058 | 49817 |
| &nbsp;&nbsp;Amortization of debt issuance costs | 432 | 891 |
| &nbsp;&nbsp;Provision for credit losses | 688 | 393 |
| &nbsp;&nbsp;Equity-based compensation expense | 24889 | 27043 |
| &nbsp;&nbsp;Change in fair value of contingent considerations | (3212) | 8092 |
| &nbsp;&nbsp;Deferred income taxes | (7455) | (12626) |
| Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable | 13385 | (10973) |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 1748 | (2473) |
| &nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses, and other liabilities | (6576) | (9774) |
| &nbsp;&nbsp;&nbsp;Deferred revenues | (15603) | (2122) |
| Other operating activities, net | (1146) | 1457 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 67508 | 31097 |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;Capital expenditures | (757) | (1210) |
| &nbsp;&nbsp;Capitalized software development costs | (18770) | (13995) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (19527) | (15205) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;Proceeds from borrowings on term loan debt |  | 6305 |
| &nbsp;&nbsp;Payment of debt issuance costs |  | (1216) |
| &nbsp;&nbsp;Payments on long-term debt | (2250) | (1505) |
| &nbsp;&nbsp;Common stock repurchase program | (38674) |  |
| &nbsp;&nbsp;Payments for business acquisition related contingent consideration | (13230) | (15156) |
| &nbsp;&nbsp;&nbsp;Payment of taxes on shares withheld for employee taxes | (5019) | (8135) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (59173) | (19707) |
| Effect of foreign exchange rate on cash and cash equivalents | 4720 | 1887 |
| Net decrease in cash and cash equivalents | (6472) | (1928) |
| Cash and cash equivalents, and restricted cash, at beginning of period | 179183 | 234951 |
| Cash and cash equivalents, and restricted cash, at end of period | $172711 | $233023 |
| **Supplemental disclosures of cash flow information** |  |  |
| Cash paid for interest | $10456 | $11171 |
| Cash paid for taxes | $8769 | $11630 |
| **Supplemental schedule of noncash investing and financing activities** |  |  |
| Stock issuance or establish liabilities related to business acquisition contingent consideration | $5670 | $3707 |

---

The accompanying notes are an integral part of the condensed consolidated financial statements.

------

**CERTARA, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)**

**(UNAUDITED)**

**1.&nbsp;&nbsp;&nbsp;&nbsp;Description of Business**

Certara, Inc. and its wholly-owned subsidiaries (together, the "Company") deliver software products and technology-driven services to customers to efficiently carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. The Company is a global leader in biosimulation, and the Company's biosimulation software and technology-driven services help optimize, streamline, or even waive certain clinical trials to accelerate programs, reduce costs, and increase the probability of success. The Company's regulatory science and market access software and services are underpinned by technologies such as regulatory submissions software, natural language processing, and Bayesian analytics. When combined, these solutions allow the Company to offer customers end-to-end support across the entire product life cycle.

The Company has operations in the United States, Australia, Canada, China, Egypt, France, Germany, Hungary, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom.

**2.&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies**

There have been no changes other than what is discussed herein to the Company's significant accounting policies as compared to the significant accounting policies described in Note 2. "Summary of Significant Accounting Policies" to the Company's audited consolidated financial statements included in the Company's 2024 Annual Report. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes as of and for the year ended December 31, 2024.

***(a)&nbsp;&nbsp;&nbsp;&nbsp;Basis of Presentation and Use of Estimates***

The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other estimates, assumptions used in the allocation of the transaction price to separate performance obligations, estimates towards the measure of progress of completion on fixed-price service contracts, the determination of fair values and useful lives of long-lived assets as well as intangible assets, goodwill, allowance for credit losses for accounts receivable, recoverability of deferred tax assets, recognition of deferred revenue, valuation of interest rate swaps, determination of fair value of equity-based awards, measurement of fair value of contingent consideration, and assumptions used in testing for impairment of long-lived assets. Actual results could differ from those estimates, and such differences may be material to the condensed consolidated financial statements.

***(b)&nbsp;&nbsp;&nbsp;&nbsp;Unaudited Interim Financial Statements***

The accompanying condensed consolidated balance sheet as of September 30, 2025, the condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30,

------

2025 and 2024, the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2025 and 2024, the condensed consolidated statements of cash flows for the nine months ended September 30, 2025 and 2024, and the related interim disclosures are unaudited.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of the Company's operations and cash flows for interim periods in accordance with U.S. GAAP. Certain amounts reported in prior periods have been reclassified to conform with the current presentation. Interim period results are not necessarily indicative of results of operations or cash flows for a full year or any subsequent interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the Company's 2024 audited consolidated financial statements and notes thereto. The information as of December 31, 2024 in the Company's condensed consolidated balance sheet included herein is derived from the Company's audited consolidated financial statements included in the Company's 2024 Annual Report.

***(c)&nbsp;&nbsp;&nbsp;&nbsp;Accounting Pronouncements Not Yet Adopted***

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The ASU requires disclosure of specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold and further disaggregation of income taxes paid for individually significant jurisdictions. The ASU will be effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the disclosures within our consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. This ASU seeks to improve of the disclosures about the types of expenses, including employee compensation, depreciation, and amortization, and costs incurred related to inventory and manufacturing activities. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. In January 2025, the FASB also issued ASU 2025-01 to clarify the effective date. The Company is currently evaluating the impact of the ASU on the disclosures within its consolidated financial statements.

In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The ASU provides a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606. In developing reasonable and supportable forecasts as part of estimating expected credit losses, all entities may elect a practical expedient that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. The ASU also provides non public entities with an accounting policy election. The ASU will be effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the consolidated financial statements.

In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The ASU removes all references to prescriptive and sequential software development stages and clarifies that the threshold for when an entity is required to start capitalizing software costs is when (1) management has authorized and committed to funding the software project and (2) it is probable that the project will be completed and the software will be used to perform the function intended. The amendments in this ASU are effective for all entities for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual

------

reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The Company is currently evaluating the impact of the ASU on the consolidated financial statements.

***(d)&nbsp;&nbsp;&nbsp;&nbsp;Principles of Consolidation***

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

***(e)&nbsp;&nbsp;&nbsp;&nbsp;Fair Value Measurements***

The Company follows FASB Accounting Standards Codification ("ASC") 820-10, "Fair Value Measurements" ("ASC 820-10"), which defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and requires certain disclosures about fair value measurements.

ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the most advantageous market for the asset or liability in an orderly transaction. Fair value measurement is based on a hierarchy of observable or unobservable inputs. The standard describes three levels of inputs that may be used to measure fair value.

Level 1 — Inputs to the valuation methodology are quoted prices available in active markets for identical securities as of the reporting date;

Level 2 — Inputs to the valuation methodology are other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk etc. as of the reporting date, and the fair value can be determined through the use of models or other valuation methodologies; and

Level 3 — Inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity of the securities and the reporting entity makes estimates and assumptions relating to the pricing of the securities including assumptions regarding risk.

If the inputs used to measure fair value fall at different levels of the fair value hierarchy, the hierarchy is based on the lowest level of input that is significant to the fair value measurement. For the acquisitions noted in Note 4, the fair value measurement methods used to estimate the fair value of the assets acquired and liabilities assumed at the acquisition dates utilized a number of significant unobservable inputs of Level 3 assumptions. These assumptions included, among other things, projections of future operating results, implied fair value of assets using an income approach by preparing a discounted cash flow analysis, and other subjective assumptions.

Interest rate swaps are valued in the market using discounted cash flows techniques. These techniques incorporate Level 1 and Level 2 inputs. The market inputs are utilized in the discounted cash flows' calculation considering the instrument's term, notional amount, discount rate and credit risk. Significant inputs to the derivative instrument valuation model for interest rate swaps are observable in active markets and are classified as Level 2 in the hierarchy.

Contingent liabilities related to acquisitions are measured at fair value using Level 3 unobservable inputs. The Company's estimates of fair value are based upon assumptions believed to be reasonable but that are uncertain and involve significant judgments by management. Any changes in the fair value of these contingent liabilities are included in the earnings in the condensed consolidated statements of operations and comprehensive income (loss).

------

The Company utilizes Monte Carlo or a series of Black-Scholes-Merton options models to estimate the fair value of the contingent consideration liabilities of business acquisitions. Significant inputs used in the fair value measurement of contingent consideration include: expected eligible revenue for the acquired businesses over the relevant measurement periods, the risk-profile of the expected eligible revenue for the acquired businesses, the uncertainty regarding the expected eligible revenue for the acquired businesses, the risk-free rate of return, the expected timing at which settlement of the contingent liabilities may occur, and the credit-adjusted discount rate associated with the risk of the Company's future liability payments.

The following table sets forth the assets and liabilities that were measured at fair value on a recurring and non-recurring basis by their levels in the fair value hierarchy at September 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **LEVEL 1** | **LEVEL 2** | **LEVEL 3** | **TOTAL** |
| | (In thousands) | (In thousands) | (In thousands) | (In thousands) |
| **<u>Assets</u>** |  |  |  |  |
| Money market funds | $81697 | $— | $— | $81697 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $81697 | $— | $— | $81697 |
| **<u>Liabilities</u>** |  |  |  |  |
| Contingent liabilities | $— | $— | $21900 | $21900 |
| Interest rate swap liabilities |  | 2594 |  | 2594 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $— | $2594 | $21900 | $24494 |

---

The following table sets forth the assets and liabilities that were measured at fair value on a recurring and non-recurring basis by their levels in the fair value hierarchy at December 31, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **LEVEL 1** | **LEVEL2** | **LEVEL 3** | **TOTAL** |
| | (In thousands) | (In thousands) | (In thousands) | (In thousands) |
| **<u>Assets</u>** |  |  |  |  |
| Money market funds | $79167 | $— | $— | $79167 |
| Interest rate swap assets |  | 2213 |  | 2213 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $79167 | $2213 | $— | $81380 |
| **<u>Liabilities</u>** |  |  |  |  |
| Contingent liabilities | $— | $— | $43939 | $43939 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $— | $— | $43939 | $43939 |

---

For the nine month period ended September 30, 2025, there were no transfers between the levels within the fair value hierarchy. The Company's Level 3 assets are interest swap assets and level 3 liabilities are acquisition related contingent consideration liabilities.

------

The following table summarizes the Level 3 activity of the changes in the contingent consideration liability.

---

| | |
|:---|:---|
| | **SEPTEMBER 30, 2025** |
| | (In thousands) |
| Beginning balance at December 31, 2024 | $43939 |
| Payments | (18900) |
| Fair value remeasurement | (3139) |
| &nbsp;&nbsp;&nbsp;&nbsp;Ending balance at September 30, 2025 | $21900 |

---

For more information regarding fair value measurements and the fair value hierarchy, see Note 2. "Summary of Significant Accounting Policies" in the notes to the consolidated financial statements in the Company's 2024 Annual Report.

***(f)&nbsp;&nbsp;&nbsp;&nbsp;Cash and Cash Equivalents***

Cash equivalents include highly liquid investments with maturities of three months or less from the date purchased. The cash and cash equivalents was $172,711 and $179,183 at September 30, 2025 and December 31, 2024, respectively.

***(g)&nbsp;&nbsp;&nbsp;&nbsp;Accounts Receivable***

Accounts receivable include current outstanding invoices billed to customers. Invoices are typically issued with net 30 days to net 90 days terms upon delivery of the product or upon achievement of billable events for service-based contracts. Unbilled receivables relate to the Company's rights to consideration for performance obligations satisfied but not billed at the reporting date on contracts. Unbilled receivables are billed and transferred to customer accounts receivable when the rights become unconditional. The carrying amount of accounts receivable is reduced by a valuation allowance.

The Company estimates the expected credit losses for accounts receivable using historical loss data adjusted for current economic conditions, including reasonable and supportable forecasts to estimate the relative size of credit losses to be expected. The Company generally writes off a receivable or records a specific allowance for credit losses if it determines that the receivable is not collectible. Allowances for credit losses of $1,937 and $2,164 were provided in the accompanying condensed consolidated financial statements as of September 30, 2025 and December 31, 2024, respectively.

Accounts receivable consists of the following:

---

| | | |
|:---|:---|:---|
| | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
| | (In thousands) | (In thousands) |
| Trade receivables | $76934 | $90609 |
| Unbilled receivables | 13677 | 13454 |
| Other receivables | 377 | 290 |
| Allowances for credit losses | (1937) | (2164) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | $89051 | $102189 |

---

------

The following table presents the information regarding the allowance for credit losses:

---

| | | |
|:---|:---|:---|
| | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
| | (In thousands) | (In thousands) |
| Beginning balance | $2164 | $1312 |
| Provision for credit losses | 688 | 1464 |
| Charge-offs, net of recoveries | (915) | (612) |
| &nbsp;&nbsp;&nbsp;&nbsp;Ending balance of allowances for credit losses | $1937 | $2164 |

---

***(h)&nbsp;&nbsp;&nbsp;&nbsp;Derivative Instruments***

In the normal course of business, the Company is subject to risk from adverse fluctuations in interest rates. The Company has chosen to manage this risk through the use of derivative financial instruments that consist of interest rate swap contracts. Counterparties to these contracts are major financial institutions. The Company is exposed to credit loss in the event of nonperformance by these counterparties. The Company does not use derivative instruments for trading or speculative purposes. The objective of managing exposure to market risk is to limit its impact on cash flows. To qualify for hedge accounting, the interest rate swaps must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions must be, and be expected to remain, probable of occurring in accordance with the related assertions.

FASB ASC 815, "Derivatives and Hedging," requires the Company to recognize all derivatives on the balance sheet at fair value. The Company may enter into derivative contracts such as interest rate swap contracts that effectively convert portions of the Company's floating rate debt to a fixed rate, which serves to mitigate interest rate risk. The Company's objectives in using interest rate swaps are to add stability to interest expense and to manage its exposure to interest rate movements. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount.

The Company entered into an interest rate swap agreement in May 2022 that pays a fixed interest rate and receives a variable interest rate to modify the interest rate characteristics of term loan debt from variable to fixed in order to reduce the impact of changes in future cash flows due to market interest rate changes. The swap agreement had a notional amount of $230,000, a fixed rate of 2.8% and a termination date of August 31, 2025. During the quarter ended September 30, 2023, the Company and the counter party amended the floating rate of the swap agreement from term LIBOR to term SOFR due to LIBOR cessation. As the swap approached maturity, the Company entered into two additional interest rate swap agreements in the second quarter of 2025, each with a notional amount of $115,000, to continue hedging the interest rate risk associated with the term loan debt. These new swaps also pay fixed interest rates and receive variable rates. The fixed interest rates are 3.62% and 3.64%. respectively. Both contracts became effective on August 31, 2025, and will mature on August 31, 2029. The Company designates these swaps as cash flow hedges at hedge inception. At September 30, 2025 and December 31, 2024, the interest swap had a fair value of $0 and $2,213 for the swap matured in August 2025, respectively. The interest swap had total fair value of $(2,594) for new swaps at September 30, 2025. The gross fair value recognized in accumulated other comprehensive income (loss) was $(2,594) and $2,213 at September 30, 2025 and December 31, 2024, respectively.

The Company uses derivatives to manage certain interest exposures and designated all the derivatives as cash flow hedges. The Company records derivatives at fair value on its condensed consolidated balance sheets. Changes in the fair value of derivatives designated as cash flow hedges are recorded as a component of accumulated other comprehensive income (loss). Those amounts are reclassified into interest expenses in the same period during which the hedged transactions impact earnings. The amount of derivative gains reclassified from accumulated other comprehensive income on derivative instruments recognized in the Company's

------

condensed consolidated statements of operations and comprehensive income (loss) was $761, $1,529, $2,645, and $4,580 for the three and nine months ended September 30, 2025 and 2024, respectively.

The notional amounts, fair values, and classification of derivative instruments in the condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024 were as follows:

---

| | | |
|:---|:---|:---|
| **Interest rate swap derivative designated as cash flow hedging instrument:** | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
|  | (In thousands) | (In thousands) |
| Notional amounts | $230000 | $230000 |
| Prepaid expenses and other current assets | $— | $2213 |
| Other current liabilities | $76 | $— |
| Other long-term liabilities | $2518 | $— |

---

The net amount of deferred loss related to derivative instruments designated as cash flow hedges that is expected to be reclassified from accumulated other comprehensive gain (loss) into earnings over the next twelve months is $76.

***(i)&nbsp;&nbsp;&nbsp;&nbsp;Revenue Recognition***

In accordance with ASC Topic 606, "Revenue from Contracts with Customers", the Company determines revenue recognition through the following steps:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Identification of the contract, or contracts, with a customer

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Identification of the performance obligations in the contract

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Determination of the transaction price

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. Allocation of the transaction price to the performance obligations in the contract

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. Recognition of revenue when, or as, the Company satisfies a performance obligation

The Company's revenue consists of fees for perpetual and term licenses for its software products, post-contract customer support (referred to as maintenance), software as a service ("SaaS"), and professional services including training and other revenue. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services.

The following describes the nature of the Company's primary types of revenues and the revenue recognition policies as they pertain to the types of transactions the Company enters into with its customers.

*Software Licenses*

Software license revenue consists primarily of sales of software licenses downloaded and installed by our customers on their own hardware. The license period is generally one year or less and includes an insignificant amount of customer support to assist the customer with the software. Software license performance obligations are generally recognized upfront at the point in time when the software license has been delivered.

------

*Software as a Service (SaaS) Revenues*

SaaS revenues consist of subscription fees for access to, and related support for, the Company's cloud-based solutions. The Company typically invoices subscription fees in advance in annual installments. The invoice is initially deferred and revenue is recognized ratably over the life of the contract. The Company's software contracts do not typically include variable consideration or options for future purchases that would not be similar to the original goods.

*Software Service* 

Maintenance services agreements on perpetual software consist of fees for providing software updates and for providing technical support for software products for a specified term. Revenue allocated to maintenance services is recognized ratably over the contract term beginning on the delivery date of each offering. Maintenance contracts generally have a term of one year. While the transfer of control of the software training and implementation performance obligations are over time, the services are typically started and completed within a few days. Due to the quick nature of the performance obligation from start to finish and the insignificant amounts, the Company recognizes any software training or implementation revenue at the completion of the service. Any unrecognized portion of amounts paid in advance for licenses and services is recorded as deferred revenue.

*Consulting Service Revenues* 

The Company's primary professional services offering includes consulting services, which may be either strategic consulting services, reporting and analysis services, regulatory writing services, or any combination of the three. The Company's professional services contracts are either time-and-materials or fixed fee. Service revenues are generally recognized over time as the services are performed. Generally, these services are delivered to customers electronically. Revenue from time-and-material contracts is recognized on an output basis as labor hours are delivered and/or direct expenses are incurred. Revenues for fixed-price services are generally recognized over time by applying input methods to estimate progress to completion. Accordingly, the number of resources being paid for and the varying lengths of time they are being paid for determine the measure of progress.

*Arrangements with Multiple Performance Obligations*

For contracts with multiple performance obligations, such as a software license plus software training, implementation, and/or maintenance/support, or in contracts where there are multiple software licenses, the Company determines if the products or services are distinct and allocates the consideration to each distinct performance obligation on a relative standalone selling price basis. The delivery of a particular type of software and each of the user licenses would be one performance obligation. Additionally, any training, implementation, or support and maintenance promises sold as part of the software license agreement would be considered separate performance obligations, as those promises are distinct and separately identifiable from the software licenses. The payment terms in these arrangements are less than one year such that there is no significant financing component.

*Contract Balances*

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (deferred revenue, contract liabilities) on the condensed consolidated balance sheets. Amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals (e.g., quarterly or monthly) or upon achievement of contractual milestones.

Contract assets relate to the Company's rights to consideration for performance obligations satisfied but not billed at the reporting date on contracts (i.e., unbilled revenue, a component of accounts receivable in the condensed consolidated balance sheets). Contract assets are billed and transferred to customer accounts

------

receivable when the rights become unconditional. The Company typically invoices customers for term licenses, subscriptions, maintenance and support fees in advance with payment due before the start of the subscription term, ranging from one to three years. The Company records the amounts collected in advance of the satisfaction of performance obligations, usually over time, as a contract liability or deferred revenue. Invoiced amounts for non-cancelable services starting in future periods are included in contract assets and deferred revenue. The portion of deferred revenue that will be recognized within 12 months is recorded as current deferred revenue, and the remaining portion is recorded as deferred revenue in the condensed consolidated balance sheets.

Contract balances at September 30, 2025, December 31, 2024 and 2023 were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** | **DECEMBER 31,<br>2023** |
| | (In thousands) | (In thousands) | (In thousands) |
| Contract assets | $13677 | $13454 | $10405 |
| Contract liabilities | $65880 | $78878 | $61748 |

---

During the nine months ended September 30, 2025, the Company recognized revenue of $69,368 related to contract liabilities at December 31, 2024.

The unsatisfied performance obligations as of September 30, 2025 were $147,586. We expect to recognize approximately $118,576 or 80.3% of this revenue over the next 12 months and the remainder thereafter.

*Deferred Contract Acquisition Costs*

Under ASC Topic 606, sales commissions paid to the sales force and the related employer payroll taxes, collectively deferred contract acquisition costs, are considered incremental and recoverable costs of obtaining a contract with a customer.

The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if it expects the benefit of those costs to be longer than one year. The Company has determined that certain sales incentive programs meet the requirements to be capitalized. The costs capitalized are primarily sales commissions for our sales force personnel. Capitalized costs to obtain a contract are amortized on a straight-line basis over the expected period of benefit. Amortization of capitalized costs is included in sales and marketing expenses in our condensed consolidated statements of operations and comprehensive income (loss).

Capitalized contract acquisition costs were $1,064 and $873 as of September 30, 2025 and December 31, 2024, respectively, and were included in prepaid expenses and other current assets in the condensed consolidated balance sheets.

*Grant Revenue*

The Company receives grant funding for certain specific projects from time to time. These grants specify the funds provided are to be used exclusively to satisfy the deliverables outlined in the grant agreements. If, under these agreements, both involved parties receive and sacrifice approximately commensurate value, they are accounted for as exchange transactions, and revenue is recognized according to ASC Topic 606. The grant funding is generally provided near contract inception, so a contract liability is initially recorded and revenue is recognized as the performance obligations are satisfied over time. If these agreements involve one party nonreciprocally transferring value to another, and any benefit to the transferor is incidental to the potential public benefits, they are accounted for as contribution transactions, and revenue is recognized in accordance with ASC Topic 958.

------

*Sources and Timing of Revenue* 

The Company's performance obligations are satisfied either over time or at a point in time. The following table presents the Company's revenue by timing of revenue recognition to understand the risks of timing of transfer of control and cash flows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Software licenses transferred at a point in time | $15435 | $10202 | $54012 | $39031 |
| Software licenses transferred over time | 28395 | 25710 | 82882 | 74395 |
| Service revenues earned over time | 60786 | 58908 | 178296 | 171361 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $104616 | $94820 | $315190 | $284787 |

---

***(j)&nbsp;&nbsp;&nbsp;&nbsp;Earnings per Share***

Basic earnings per common share is computed by dividing the net earnings by the weighted-average number of shares outstanding during the reporting period, without consideration for potentially dilutive securities. Diluted shares are calculated under the treasury stock method. Diluted earnings per share is calculated by dividing the net earnings attributable to stockholders by the weighted-average number of shares and dilutive securities outstanding during the period.

**3.&nbsp;&nbsp;&nbsp;&nbsp;Concentrations of Credit Risk**

Financial instruments that potentially subject the Company to concentrations of credit risk have consisted principally of cash and cash equivalent investments and trade receivables. The Company invests available cash in bank deposits, investment-grade securities, and short-term interest-producing investments, including government obligations and other money market instruments. At September 30, 2025 and December 31, 2024, the investments were bank deposits, overnight sweep accounts, and money market funds. The Company has adopted credit policies and standards to evaluate the risk associated with sales that require collateral, such as letters of credit or bank guarantees, whenever deemed necessary. Management believes that any risk of loss is significantly reduced due to the nature of the customers and distributors with which the Company does business.

As of September 30, 2025 and December 31, 2024, no single customer accounted for more than 10% of the Company's accounts receivable. No single customer accounted for more than 10% of the Company's revenues during the nine months ended September 30, 2025 and 2024.

**4.&nbsp;&nbsp;&nbsp;&nbsp;Business Combinations**

Acquisitions have been accounted for by using the acquisition method of accounting pursuant to FASB ASC 805, "Business Combinations." Amounts allocated to the purchased assets and liabilities assumed are based upon the total purchase price and the estimated fair values of such assets and liabilities on the effective date of the purchase as determined by an independent third party. The results of operations for the acquisitions have been included in the Company's results of operations prospectively from the date of acquisition.

Since 2013, and as of September 30, 2025, the Company has completed 21 acquisitions, of which 14 have included software or technology. Details of acquisitions that have closed since the beginning of fiscal year 2024 are provided below.

------

***Chemaxon, Kft. ("Chemaxon")***

On October 1, 2024, the Company acquired 100% of the equity of Chemaxon, a leading cheminformatics company that provides platforms, applications, and solutions to handle chemical entities in life sciences, biotechnology, agrochemicals, new materials, education, and other research industries, for total estimated consideration of $96,401. The acquisition strategically positions Certara in the drug discovery biosimulation market at scale. It complements Certara's existing biosimulation portfolio which is widely used in later phases of drug development. The business combination was not material to the Company's consolidated financial statements.

During the first half of 2025, the Company recorded a $2,947 adjustment to goodwill and deferred tax balances related to the Chemaxon acquisition, reflecting updates to the purchase price allocation. Based on the Company's purchase price allocation, approximately $36,000, $11,000, $2,900, $330 and $49,430 of the purchase price were assigned to developed technology, customer relationship, trademark, non-compete agreements, and goodwill, respectively. The Company does not expect goodwill to be deductible due to the fact the Company treated the acquisition as a stock acquisition under the relevant sections of the Internal Revenue Code.

The results of operations of the acquired businesses and the fair value of the acquired assets and liabilities assumed are included in the Company's condensed consolidated financial statements with effect from the date of the acquisitions.

**5.&nbsp;&nbsp;&nbsp;&nbsp;Prepaid Expenses and Other Current Assets and Other Long-Term Assets**

Prepaid expense and other current assets at September 30, 2025 and December 31, 2024 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
| | (In thousands) | (In thousands) |
| Prepaid expenses | $9201 | $8315 |
| Income tax receivable | 2500 | 9341 |
| Research and development tax credit receivable | 6924 | 7554 |
| Current portion of interest rate swap asset |  | 2213 |
| Other current assets | 2916 | 2057 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | $21541 | $29480 |

---

Other long-term assets at September 30, 2025 and December 31, 2024 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
| | (In thousands) | (In thousands) |
| Long-term deposits | $1289 | $1457 |
| Deferred financing cost | 507 | 574 |
| &nbsp;&nbsp;Total other long-term assets | $1796 | $2031 |

---

------

**6.&nbsp;&nbsp;&nbsp;&nbsp;Long-Term Debt and Revolving Line of Credit**

The Company has been a party to a Credit Agreement since August 2017 that provides for a senior secured term loan and commitments under a revolving credit facility (as amended, the "Credit Agreement"). On June 26, 2024, the Company entered into the Fifth Amendment to its Credit Agreement (the "Amendment"), which primarily (1) amended the principal amount of the term loan to $300,000 and its maturity date to June 26, 2031; and (2) extended the termination date associated with the $100,000 revolving credit commitment to June 26, 2029. The term loan under this Amendment has substantially the same terms as the existing term loans and revolving credit commitments. The Credit Agreement is collateralized by substantially all U.S. assets and stock pledges for the non-U.S. subsidiaries and contains various financial and nonfinancial covenants.

As multiple lenders syndicated funds under the credit agreements, the Company assessed whether existing debt was modified, extinguished, or if new debt was issued under GAAP guidelines. This evaluation was conducted separately for each lender's portion of the loans and commitments in the syndication, treating each lender's participation as if separate debt instruments existed. The Company either deferred and amortize debt issuance costs or recognized expenses or losses, according to the applicable accounting guidance for each category.

Borrowings under the Credit Agreement bear interest at a rate per annum equal to, at the election of the Borrowers, either (i) the Term SOFR rate, with a floor of 0.00% plus an applicable margin rate of 3.00% for the Term Loans and between 2.75% and 3.50% for loans under the Revolving Facility, depending on the applicable first lien leverage ratio, or (ii) an Alternate Base Rate ("ABR"), with a floor of 1.00%, plus an applicable margin rate of 2.00% for the Term Loans or between 1.75% and 2.50% for loans under the Revolving Facility, depending on the applicable first lien leverage ratio. The ABR is determined as the greatest of (a) the prime rate, (b) the federal funds effective rate, plus 0.50%, and (c) the Term SOFR rate plus 1.00%. Additionally, the Company is obligated to pay a commitment fee of the unused amount and other customary fees. Moreover, in October 2025, the Company entered into a Sixth Amendment to its Credit Agreement, which, among other changes, reduced the applicable rate for existing term loans. For further details on the Sixth Amendment, see Note 14, "Subsequent Event".

As of each of September 30, 2025 and December 31, 2024, available borrowings under the revolving lines of credit were $100,000.

The effective interest rate was 7.39% and 8.96% for the nine months ended September 30, 2025 and 2024, respectively, for the term loan debt. As discussed previously, the Company entered into interest rate swap agreements and continues to use the swap to mitigate the interest risk for the Company's debt obligations under the Credit Agreement.

Interest incurred on the Credit Agreement with respect to the term loan amounted to $5,535, $6,366, $16,499 and $19,900 for the three and nine months ended September 30, 2025 and 2024, respectively. Accrued interest payable on the Credit Agreement with respect to the term loan amounted to $58 and $61 at September 30, 2025 and December 31, 2024, respectively, and is included in accrued expenses. Commitment fees incurred for the undrawn balance of the revolving line of credit was $64, $81, $231 and $207 for the three and nine months ended September 30, 2025 and 2024, respectively. There was $1 accrued interest payable on the revolving line of credit as of each of September 30, 2025 and December 31, 2024.

------

Long-term debt consists of the following:

---

| | | |
|:---|:---|:---|
| | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
| | (In thousands) | (In thousands) |
| Term loans | $296250 | $298500 |
| Revolving line of credit |  |  |
| Less: debt issuance costs | (2709) | (3075) |
| Total | 293541 | 295425 |
| Current portion of long-term debt | (3000) | (3000) |
| Long-term debt, net of current portion and debt issuance costs | $290541 | $292425 |

---

The principal amount of long-term debt outstanding as of September 30, 2025 matures in the following years:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Remainder of 2025** | **2026** | **2027** | **2028** | **2029** | **Thereafter** | **TOTAL** |
| | (In thousands) | (In thousands) | (In thousands) | (In thousands) | (In thousands) | (In thousands) | (In thousands) |
| Maturities | $750 | $3000 | $3000 | $3000 | $3000 | $283500 | $296250 |

---

The Credit Agreements require the Company to make an annual mandatory prepayment as it relates to the Company's Excess Cash Flow calculation. For the year ended December 31, 2024, the Company was not required to make a mandatory prepayment on the term loan. Under the Credit Agreement (as amended by the Amendment), the Company is required to make a quarterly principal payment of $750 on the term loans starting September 30, 2024.

The fair values of the Company's variable interest term loan and revolving line of credit are not significantly different than their carrying value because the interest rates on these instruments are subject to change with market interest rates.

**7.&nbsp;&nbsp;&nbsp;&nbsp;Leases**

The Company leases certain office facilities and equipment under non-cancelable operating leases with remaining terms ranging from less than one to nine years.

Operating lease ROU assets are included in other assets. With respect to operating lease liabilities, current operating lease liabilities are included in current liabilities and non-current operating lease liabilities are included in long-term liabilities in the condensed consolidated balance sheets. At September 30, 2025, the weighted average remaining lease terms were 5.8 years for operating leases, and the weighted average discount rate was 5.7% for operating leases. For additional information on the Company's leases, see Note 13. "Leases" to the consolidated financial statements included in the Company's 2024 Annual Report.

------

The following table summarizes the lease-related assets and liabilities recorded in the condensed consolidated balance sheets at September 30, 2025 and December 31, 2024:

---

| | | | |
|:---|:---|:---|:---|
| **<u>Lease Position</u>** | **Balance Sheet Classification** | **SEPTEMBER 30, 2025** | **DECEMBER 31, 2024** |
|  |  | (In thousands) | (In thousands) |
| **<u>Assets</u>** |  |  |  |
| Operating lease assets | Operating lease right-of-use assets | $12371 | $13841 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease assets |  | $12371 | $13841 |
| **<u>Liabilities</u>** |  |  |  |
| Current |  |  |  |
| &nbsp;&nbsp;Operating | Other current liabilities | $4099 | $5306 |
| Noncurrent |  |  |  |
| &nbsp;&nbsp;Operating | Operating lease liabilities, net of current portion | 8965 | 11166 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease liabilities |  | $13064 | $16472 |

---

The following table summarizes by year the maturities of our minimum lease payments as of September 30, 2025:

---

| | |
|:---|:---|
| | **OPERATING<br>LEASES** |
| | (In thousands) |
| Remainder of 2025 | $1581 |
| 2026 | 4040 |
| 2027 | 2946 |
| 2028 | 1214 |
| 2029 | 1179 |
| Thereafter | 5206 |
| Total future lease payments | 16166 |
| Less: imputed interest | (3102) |
| Total | $13064 |

---

------

**8.&nbsp;&nbsp;&nbsp;&nbsp;Accrued Expenses and Other Liabilities** 

Accrued expenses consist of the following:

---

| | | |
|:---|:---|:---|
| | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
| | (In thousands) | (In thousands) |
| Accrued compensation | $29319 | $31045 |
| Legal and professional accruals | 3974 | 2886 |
| Interest payable | 58 | 51 |
| Income taxes payable | 2515 | 430 |
| Short-term contingent consideration liabilities | 22364 | 20887 |
| Other | 1635 | 1152 |
| Total accrued expenses | $59865 | $56451 |

---

Other long-term liabilities consist of the following:

---

| | | |
|:---|:---|:---|
| | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
| | (In thousands) | (In thousands) |
| Uncertain tax position liability | $1800 | $1718 |
| Derivative Liabilities - Long-term | 2518 |  |
| Contingent consideration - long term |  | 23581 |
| Total other long-term liabilities | $4318 | $25299 |

---

**9.&nbsp;&nbsp;&nbsp;&nbsp;Equity-Based Compensation**

The Company's equity-based compensation programs are intended to attract, retain and provide incentives for employees, officers, and directors. The Company has the following stock-based compensation plans and programs.

***Restricted Stock***

The majority of the Company's restricted stock awarded to its employees was originally issued on December 10, 2020 in exchange for the Class B Profits Interest Unit (the "Class B Units") of EQT Avatar Parent LP, which was the former parent of the Company.

Share-based compensation for the restricted stock exchanged for the time-based Class B Units is recognized on a straight-line basis over the requisite service period of the award, which is generally five years. Share-based compensation for the restricted stock exchanged for the performance-based Class B Units is recognized using

------

the accelerated attribution approach. As of September 30, 2025, all of the Company's restricted stock had fully vested, and no restricted stock remained outstanding.

---

| | | |
|:---|:---|:---|
| | **SHARES** | **WEIGHTED-<br>AVERAGE<br>GRANT DATE<br>FAIR VALUE** |
| Non-vested restricted stock as of December 31, 2024 | 157486 | $22.94 |
| &nbsp;&nbsp;Granted |  |  |
| &nbsp;&nbsp;Vested | (157486) | 22.94 |
| &nbsp;&nbsp;Forfeited |  |  |
| Non-vested restricted stock as of September 30, 2025 |  | $— |

---

Equity-based compensation expenses related to the restricted stock exchanged for performance-based Class B Units were $39, $173, $160, and $579 for the three and nine months ended September 30, 2025 and 2024, respectively. As of September 30, 2025, all compensation expense related to the awards had been fully recognized.

Equity-based compensation expenses related to the restricted stock exchanged for time-based Class B Units were $80, $196, $321 and $794 for the three and nine months ended September 30, 2025 and 2024, respectively. As of September 30, 2025, all compensation expense related to the awards had been fully recognized.

In order to align the Company's equity compensation program with public company practices, the Company's Board of Directors adopted and stockholders approved the 2020 Incentive Plan. The 2020 Incentive Plan allows for grants of non-qualified stock options, incentive stock options, restricted stock, restricted stock units ("RSUs"), and performance stock units ("PSUs") to employees, directors, officers, and consultants or advisors of the Company. The 2020 Incentive Plan allows for 20,000,000 shares (the "plan share reserve") of common stock to be issued. No more than the number of shares of common stock equal to the plan share reserve may be issued in aggregate pursuant to the exercise of incentive stock options. The maximum number of shares of common stock granted during a single fiscal year to any non-employee director, taken together with any cash fees paid to such non-employee director during the fiscal year, may not exceed $1,000,000 in total value, except for certain awards made to a non-executive chair of our Board of Directors.

***Restricted Stock Units***

RSUs represent the right to receive shares of the Company's common stock at a specified date in the future. The fair value of the RSUs is based on the fair value of the underlying shares on the date of grant.

------

A summary of the Company's RSU activity is as follows:

---

| | | |
|:---|:---|:---|
| | **UNITS** | **WEIGHTED-<br>AVERAGE<br>GRANT DATE<br>FAIR VALUE** |
| Non-vested RSUs as of December 31, 2024 | 3204589 | $19.61 |
| &nbsp;&nbsp;Granted | 2164196 | 11.23 |
| &nbsp;&nbsp;Vested\* | (1362259) | 20.55 |
| &nbsp;&nbsp;Forfeited | (232564) | 18.54 |
| Non-vested RSUs as of September 30, 2025 | 3773962 | $14.53 |

---

___________________________________

\* The number of the RSUs vested included 484,483 shares that were withheld on behalf of employees to satisfy the statutory tax withholding requirements.

Equity-based compensation expenses related to the RSUs were $7,496, $8,069, $19,736 and $24,388 for three and nine months ended September 30, 2025 and 2024, respectively. At September 30, 2025, the total unrecognized equity-based compensation expense related to outstanding RSUs was $41,355, which is expected to be recognized over a weighted-average period of 22.8 months.

***Performance Stock Units***

PSUs are issued under the 2020 Incentive Plan and represent the right to receive shares of the Company's common stock at a specified date in the future based on the satisfaction of various service conditions and the achievement of certain performance thresholds, including year over year revenue growth, unlevered free cash flow growth, annual revenue, and annual EBITDA. The PSUs granted in 2023, 2024, and 2025 also contain market conditions.

Share-based compensation for the PSUs is only recognized to the extent a threshold is probable of being achieved and is recognized using the accelerated attribution approach. The Company will continue to assess the probability of each condition being achieved at each reporting period to determine whether and when to recognize compensation costs.

A summary of the Company's PSU activity for the period ended September 30, 2025 is as follows:

---

| | | |
|:---|:---|:---|
| | **UNITS** | **WEIGHTED-<br>AVERAGE<br>GRANT DATE<br>FAIR VALUE** |
| Non-vested PSUs as of December 31, 2024 | 645377 | $20.95 |
| &nbsp;&nbsp;Granted | 1168442 | 10.09 |
| &nbsp;&nbsp;Vested |  |  |
| &nbsp;&nbsp;Forfeited | (3322) | 23.24 |
| Cancelled\* | (201138) | 22.13 |
| Non-vested PSUs as of September 30, 2025 | 1609359 | $12.91 |

---

__________________________________

\*During the first nine months of 2025, the Company cancelled 201,138 PSU shares that did not meet the required performance conditions for vesting.

------

Equity-based compensation expenses (income) related to the PSUs were $1,959, $(358), $4,672 and $964 for the three and nine months ended September 30, 2025 and 2024, respectively. At September 30, 2025, the total unrecognized equity-based compensation expense related to outstanding PSUs was $7,439, which is expected to be recognized over a weighted-average period of 18.15 months.

The following table summarizes the components of total equity-based compensation expense included in the condensed consolidated statements of operations and comprehensive income (loss) for each period presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Cost of revenues | $3251 | $3235 | $8849 | $10095 |
| Sales and marketing | 1213 | 865 | 3103 | 2546 |
| Research and development | 1072 | 1302 | 2673 | 4306 |
| General and administrative | 4038 | 2785 | 10264 | 10096 |
| &nbsp;&nbsp;Total | $9574 | $8187 | $24889 | $27043 |

---

**10. &nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies**

*Contingent consideration*

In connection with certain of the Company's business acquisitions, the Company is required to pay additional consideration if the acquired businesses achieve certain eligible revenue thresholds for certain periods. Furthermore, the Company agreed to pay additional contingent consideration related to a business acquisition, contingent on the resolution of certain tax-related contingencies. For the nine months ended September 30, 2025, the Company paid contingent consideration of $18,900, consisting of $13,230 in cash and $5,670 in Company stock. The total contingent liabilities were $22,364 and $44,468 at September 30, 2025 and December 31, 2024, respectively. The contingent liabilities are included in accrued expenses and other long-term liabilities in the Company's condensed consolidated balance sheet.

*Legal proceedings*

The Company does not have any pending or threatened litigation which, individually or in the aggregate, would have a material adverse effect on its condensed consolidated financial statements as of September 30, 2025.

*Assurance-type warranty*

The Company includes an assurance commitment warranting that the application software products will perform in accordance with written user documentation and the agreements negotiated with customers. Since the Company does not customize its application software, warranty costs have historically been insignificant and expensed as incurred.

For information related to commitments for future minimum lease payments, please see Note 7.<u>["Leases"](#if278e3577cb24443aabadc27af2f7e0f_58)</u>.

------

**11.&nbsp;&nbsp;&nbsp;&nbsp;Segment Data**

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance.

The Company has determined that its chief executive officer ("CEO") is its CODM. The Company manages its operations as a single segment for the purpose of assessing and making operating decisions. The Company's CODM allocates resources and assesses performance based upon financial information at the consolidated level. The accounting policies of the Company's single segment are the same as those described in the summary of significant accounting policies. The inter-companies balances and transactions are eliminated.

As the Company operates and reports in a single reportable segment, the Company's CODM assesses performance for the segment and decides how to allocate resources based on net income that also is reported on the income statement as consolidated net income. The measure of segment assets is reported on the balance sheet as total consolidated assets.

The CODM uses net income and other performance indicators to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits into the segment or into other parts of the entity, such as for acquisitions. Net income is also used to monitor budget versus actual results.

The Company manages the business activities on a consolidated basis. The Company's operating segment provides technology-enabled services and software products to its customers. The Company's revenue consists of fees for its software products and services. The revenue is primarily generated from Americas. See item (i) - Revenue recognition under Note 2. "Summary of Significant Accounting Policies", for a description of the Company's revenue categories.

The following table summarizes revenue by geographic area for the three and nine months ended September 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED<br>SEPTEMBER 30,** | **THREE MONTHS ENDED<br>SEPTEMBER 30,** | **NINE MONTHS ENDED<br>SEPTEMBER 30,** | **NINE MONTHS ENDED<br>SEPTEMBER 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | (In thousands) | (In thousands) | (In thousands) | (In thousands) |
| Revenue(1): |  |  |  |  |
| &nbsp;&nbsp;Americas | $73997 | $69906 | $218945 | $208690 |
| &nbsp;&nbsp;EMEA | 21915 | 18117 | 71067 | 56205 |
| &nbsp;&nbsp;Asia Pacific | 8704 | 6797 | 25178 | 19892 |
| &nbsp;&nbsp;Total | $104616 | $94820 | $315190 | $284787 |

---

___________________________________

(1)&nbsp;&nbsp;&nbsp;&nbsp;Revenue is attributable to the countries based on the location of the customer.

------

The following table presents information about reported segment revenue, segment profit or loss, and significant segment expenses.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED<br>SEPTEMBER 30,** | **THREE MONTHS ENDED<br>SEPTEMBER 30,** | **NINE MONTHS ENDED<br>SEPTEMBER 30,** | **NINE MONTHS ENDED<br>SEPTEMBER 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | (In thousands) | (In thousands) | (In thousands) | (In thousands) |
| Revenues | $104616 | $94820 | $315190 | $284787 |
| Less: |  |  |  |  |
| Employee expense-non equity | 58703 | 53763 | 178227 | 167421 |
| Equity-based compensation expense | 9574 | 8187 | 24889 | 27043 |
| Equipment and software expense | 4261 | 3227 | 12595 | 10194 |
| Direct cost of revenues | 1647 | 1262 | 5336 | 3564 |
| Professional services expense | 6886 | 6216 | 21477 | 18815 |
| Change in fair value of contingent consideration | 2689 | 2431 | (3212) | 8092 |
| Depreciation and amortization | 18626 | 16792 | 56058 | 49817 |
| Other segment expense (income)\* | (2514) | (584) | (5325) | 2689 |
| Interest expense | 5011 | 5187 | 14619 | 16516 |
| Income tax expense (benefit) | (1792) | (290) | 6226 | (736) |
| Segment net income (loss) | $1525 | $(1371) | $4300 | $(18628) |
| Reconciliation of profit or loss |  |  |  |  |
| Adjustments and reconciling items |  |  |  |  |
| Consolidated net income (loss) | $1525 | $(1371) | $4300 | $(18628) |

---

&nbsp;&nbsp;&nbsp;&nbsp;\* Other segment expense (income) items included in segment net income include facilities related expense, marketing, travel, insurance, foreign currency exchange gains and losses, and other overhead expense.

**12.&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes**

The Company generally records its interim tax provision based upon a projection of the Company's estimated annual effective tax rate ("EAETR"). This EAETR is applied to the year-to-date consolidated pre-tax income to determine the interim provision for income taxes before discrete items. The effective tax rate ("ETR") each period is impacted by a number of factors, including the relative mix of domestic and international earnings, permanent differences, adjustments to the valuation allowances, and discrete items. The currently forecasted ETR may vary from the actual year-end due to the changes in these factors.

The Company's global ETR for the three and nine months ended September 30, 2025 and 2024 were 671%, 17%, 59%, and 4%, respectively, including discrete tax items. The current year increase in the ETR was principally due to the combined effect of the overall increase in pre-tax book income, the impact of non-deductible items, and the tax effect of certain discrete items.

On July 4, 2025, the United States enacted the One Big Beautiful Bill Act (the "OBBBA"), which includes changes to U.S. tax law such as significant amendments to the U.S. federal income tax code. Key provisions include the permanent reinstatement of immediate expensing for domestic research expenditures, the restoration of full expensing for qualified machinery, equipment and other short-lived assets, and several modifications to existing international tax provisions.The Company is in the process of evaluating the impact of the OBBBA.

------

**13.&nbsp;&nbsp;&nbsp;&nbsp;Earnings per Share**

Basic earnings per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average common shares outstanding for the period. Diluted earnings per share is computed by dividing the net income (loss) attributable to stockholders by the weighted-average number of shares and dilutive potential common shares during the period.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** |
| | **2025** | **2024** | **2025** | **2024** |
|  | (In thousands, except per share and share data) | (In thousands, except per share and share data) | (In thousands, except per share and share data) | (In thousands, except per share and share data) |
| &nbsp;&nbsp;Net income (loss) available to common shareholders | $1525 | $(1371) | $4300 | $(18628) |
| &nbsp;&nbsp;Basic weighted-average common shares outstanding | 160403011 | 160642052 | 160769603 | 160225375 |
| Basic earnings per common share | $0.01 | $(0.01) | $0.03 | $(0.12) |
| **Diluted earnings per share** |  |  |  |  |
| &nbsp;&nbsp;Net income (loss) available to common shares | $1525 | $(1371) | $4300 | $(18628) |
| &nbsp;&nbsp;Basic weighted-average common shares outstanding | 160403011 | 160642052 | 160769603 | 160225375 |
| &nbsp;&nbsp;Dilutive potential common shares | 197559 |  | 494273 |  |
| &nbsp;&nbsp;Diluted weighted-average common shares outstanding | 160600570 | 160642052 | 161263876 | 160225375 |
| Diluted earnings per common share | $0.01 | $(0.01) | $0.03 | $(0.12) |

---

__________________________________

(a) For the three- and nine-months ended September 30, 2025, the Company repurchased 1,230,398 and 3,023,677 shares of its common stock, respectively, under the stock repurchase program authorized by the Company's Board of Directors on April 11, 2025. The program authorizes the Company to repurchase up to $100,000 of its common stock.

(b) For the three- and nine-months ended September 30, 2024, the Company excluded potentially dilutive securities from the calculation of diluted earnings per share that could potentially dilute earnings per share in the future because of the anti-dilutive effect of the reported net loss.

**14.&nbsp;&nbsp;&nbsp;&nbsp;Subsequent Event**

On October 16, 2025, the Company entered into a Sixth Amendment ("Amendment") to its Credit Agreement, originally dated August 15, 2017. This Amendment provides for, among other changes, a reduction in the applicable rate for term loans. Such modifications were implemented through the establishment of Replacement Term Loans under the Credit Agreement. The Replacement Term Loans bear interest at a rate per annum equal to, at the election of the Borrowers, either (i) the Term SOFR rate, with a floor of 0.00% plus an applicable margin rate of 2.75% or (ii) an Alternate Base Rate ("ABR"), with a floor of 1.00%, plus an applicable margin rate of 1.75%. The ABR is determined as the greatest of (a) the prime rate, (b) the federal funds effective rate, plus 0.50% and (iii) the Term SOFR rate plus 1.00%. The Replacement Term Loans are subject to substantially similar terms currently relating to guarantees, collateral, mandatory prepayments and covenants that were applicable to the Company's Existing Term Loans prior to giving effect to the Amendment.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion summarizes the significant factors affecting the operating results, financial condition, liquidity, and cash flows of our Company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report and our 2024 Annual Report. The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity, and capital resources, and all other non-historical statements in this discussion are forward-looking statements and are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly in the section "Special Note Regarding Forward-Looking Statements" of this Quarterly Report.*

*We intend the discussion of our financial condition and results of operations that follows to provide information that will assist the reader in understanding our condensed consolidated financial statements, the changes in certain key items in those financial statements from period to period, and the primary factors that accounted for those changes, as well as how certain accounting principles, policies, and estimates affect our condensed consolidated financial statements.*

**Executive Overview**

We are a global leader in biosimulation technology and solutions for using Model-Informed Drug Development ("MIDD") in the global biopharmaceutical industry. Biosimulation and MIDD can increase the probability of success in bringing a new drug to market and decrease the costs of drug development. In addition, MIDD strategies are increasingly utilized to help predict commercial success, a critical part of the drug development process as new products must be both approved by regulators and adopted by the market. Our goal is to enable the life science industry to use data, modeling, and analytics to make better decisions during drug development and commercialization to increase productivity rates and vastly reduce development costs.

Drug development is necessarily a highly regulated process involving the collection of vast amounts of laboratory, clinical and evidence data, and there are many failures at every step along the way which add to total cost. On average, the pharmaceutical industry spends more than $270 billion annually on research and development ("R&D"). Generally, companies spend an average of $6.2 billion per FDA-approved drug to develop one new medicine, including the cost of failures, according to "Analysis of pharma R&D productivity - a new perspective needed" on Drug Discovery Today. Our software and scientists incorporate modern advances in scientific understanding, drug development experience, data analysis, and AI resulting in significant opportunities to decrease the cost and increase the odds of new drug approval and commercial success.

Our proprietary biosimulation platforms are built on biology, chemistry, and pharmacology principles with proprietary mathematical algorithms that model how medicines and diseases behave in the body. For over two decades, our scientists have developed and validated our biosimulation technology using data from scientific literature, laboratory research, preclinical and clinical studies. To do this, we have developed solutions for the collection, standardization, validation, storage, and analysis of the preclinical and clinical data needed for MIDD. These data solutions are used internally and by global life sciences companies.

The scientific principles underlying our work must be transparent and fully explainable during the regulatory process, so we have developed expertise in incorporating data and results into regulatory documents. Our software and regulatory services streamline the creation of regulatory filings and speed regulatory data flow to maximize the chances of successful commercialization.

------

AI and machine learning technologies are being incorporated across our software and services portfolios, providing opportunities to expand the number of data sources utilized, better predict outcomes, and streamline reporting. For example, we are using machine learning to automate and speed the process of biosimulation, and we have created an AI application to aid in drafting regulatory documents from scientific analyses and clinical data. We believe that AI predictive models will continue to enhance the accuracy and usefulness of biosimulation models and will be utilized broadly across drug development.

We deliver software and technology-enabled services. Our strategy is to create and apply validated software applications that can be used broadly in the life science industry. We offer services, leveraging our technology, delivered by scientists with extensive drug development experience to aid our clients in applying biosimulation and MIDD to their specific projects.

Since 2014, customers who leverage our solutions have received 90% or more of all new drug approvals by FDA. We have worked with more than 2,400 life sciences companies and academic institutions and have collaborated on more than 9,000 customer projects in the last decade across a wide variety of therapeutic areas ranging from cancer and hematology to diabetes and hundreds of rare diseases. Our software products are licensed by more than 94,000 users and are also used by 23 global drug regulatory agencies, including the FDA and Japan's Pharmaceuticals and Medical Devices Agency (the "PMDA").

With continued innovation in and adoption of our biosimulation software, technology, and services, we believe more life science companies worldwide will leverage more of our end-to-end platform to reduce cost, accelerate speed to market, and ensure safety and efficacy of medicines for all patients.

**Key Factors Affecting Our Performance**

We believe that the growth and future success of our business depend on many factors. While each of these factors presents significant opportunities for our business, they also pose important challenges that we must successfully address to sustain our growth and improve the results of our operations.

**Customer Retention and Expansion**

Our future operating results depend, in part, on our ability to successfully enter new markets, increase our customer base, and retain and expand our relationships with existing customers. We monitor two key performance indicators to evaluate retention and expansion: new bookings and net retention rates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Bookings: Our new bookings represent the estimated contract value of a signed contract or purchase order where there is sufficient or reasonable certainty about the customer's ability and intent to fund and commence the software and/or services. Bookings vary from period to period depending on numerous factors, including the overall health of the biopharmaceutical industry, regulatory developments, industry consolidation, and sales performance. Bookings have varied and will continue to vary significantly from quarter to quarter and from year to year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net Retention Rates: Our net retention rates measure the percentage of recurring revenue that is retained from existing software customers over a specific period of time, inclusive of price increases and expansion, excluding revenue from acquisitions occurred within the past 12 months.

------

The table below summarizes our quarterly bookings and net software retention rate trends:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
| | **Q1** | **Q2** | **Q3** | **Q1** | **Q2** | **Q3** |
| | (in millions except percentage) | (in millions except percentage) | (in millions except percentage) | (in millions except percentage) | (in millions except percentage) | |
| Bookings | $118.2 | $112.0 | $96.6 | $105.8 | $98.9 | $96.1 |
| Net Retention Rates | 102.4% | 107.6% | 103.9% | 114.1% | 108.0% | 107.6% |

---

**Investments in Growth**

We have invested and intend to continue to invest in expanding the breadth and depth of our solutions, including through acquisitions and international expansion. We expect to continue to invest in (i) scientific talent to expand our ability to deliver solutions across the drug development spectrum; (ii) sales and marketing to promote our solutions to new and existing customers and in existing and expanded geographies; (iii) research and development to support existing solutions and innovate new technology; (iv) other operational and administrative functions to support our expected growth; and (v) complementary businesses. We expect that our headcount and our total operating expenses will continue to increase over time.

**Our Operating Environment**

The acceptance of model-informed biopharmaceutical discovery and development by regulatory authorities affects the demand for our products and services. Support for the use of biosimulation in discovery and development from regulatory bodies, such as the FDA and European Medicines Agency, has been critical to its rapid adoption by the biopharmaceutical industry. There has been a steady increase in the recognition by regulatory and academic institutions of the role that modeling and simulation can play in the biopharmaceutical development and approval process, as demonstrated by new regulations and guidance documents describing and encouraging the use of modeling and simulation in the biopharmaceutical discovery, development, testing, and approval process, which has directly led to an increase in the demand for our products and services. Changes in government or regulatory policy, or a reversal in the trend toward increasing the acceptance of and reliance upon in silico data in the drug approval process, could decrease the demand for our products and services or lead regulatory authorities to cease use of, or recommend against the use of, our products and services.

Governmental agencies throughout the world, but particularly in the United States where the majority of our customers are based, strictly regulate the biopharmaceutical development process. Our business involves helping biopharmaceutical companies strategically and tactically navigate the regulatory approval process. New or amended regulations are expected to result in higher regulatory standards and often additional revenues for companies that service these industries. However, some changes in regulations, such as a relaxation in regulatory requirements or the introduction of streamlined or expedited approval procedures, or an increase in regulatory requirements that we have difficulty satisfying or that make our regulatory strategy services less competitive, could eliminate or substantially reduce the demand for our regulatory services. Additionally, a new government administration may lead to either stricter or more relaxed regulatory environments. Currently, the new U.S. federal administration shows signs of reforming the pharmaceutical industry, particularly focusing on drug pricing and accelerated drug approval. These changes are expected to potentially have a significant impact on the biopharmaceutical industries, creating a mix of opportunities and challenges for us.

On October 1, 2025, the U.S. federal government experienced a shutdown, resulting in certain regulatory agencies, including the U.S. Food and Drug Administration ("FDA") and the U.S. Securities and Exchange Commission ("SEC"), furloughing employees and temporarily suspending various activities. We have not experienced any material impacts to our operations or financials but continue to monitor the impacts. If the government shutdown continues for an extended period, it could increase uncertainty in the overall economic

------

environment and adversely impact business operations across multiple industries, including the pharmaceutical industry. Prolonged delays or disruptions in regulatory reviews, approvals, or filings could adversely affect our operations, financial condition, and results of operations.

In addition to the external regulatory environment, internally, we initiated a review process in 2024 to evaluate the long-term strategic options for our regulatory services business. This review could result in several potential directions for the business, which could potentially have a significant impact on our operations.

**Competition**

The market for our biosimulation products and related services for the biopharmaceutical industry is competitive and highly fragmented. In our view, the principal competitive factors in our market are the functionality and quality of models, the breadth of molecular types, therapeutic areas, and modalities supported, regulator acceptance of our solutions, ease of use and functionality of applications, depth of experience in drug development, brand awareness and reputation, total cost, and the ability to securely integrate with other enterprise applications and the overall drug development process in the customer.

**Macroeconomic Conditions**

Uncertain macroeconomic conditions, including higher inflation, rising interest rates and instability in the financial system, trade disputes, tariffs, changes in government funding, geopolitical conflicts, and pandemics or other infectious disease outbreaks, may pose challenges to our business.

Non-GAAP Measures

Management uses various financial metrics, including total revenues, income from operations, net income, and certain metrics that are not required by, or presented in accordance with, GAAP, such as adjusted EBITDA, adjusted net income, and adjusted diluted earnings per share, to measure and assess the performance of our business, to evaluate the effectiveness of our business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare our performance against that of other peer companies using similar measures. We believe that the presentation of the GAAP and the non-GAAP metrics in this filing will aid investors in understanding our business.

Management measures operating performance based on adjusted EBITDA defined for a particular period as net income (loss) excluding interest expense, provision (benefit) for income taxes, depreciation and amortization expense, intangible asset amortization, equity-based compensation expense, change in fair value of contingent consideration, acquisition, and other items not indicative of our ongoing operating performance. Management also measures operating performance based on adjusted net income defined for a particular period as net income (loss) excluding equity-based compensation expense, amortization of acquisition-related intangible assets, goodwill impairments, change in fair value of contingent consideration, acquisition and integration expense, and other items not indicative of our ongoing operating performance. Further, management measures operating performance based on adjusted diluted earnings per share defined for a particular period as adjusted net income divided by the weighted-average diluted common shares outstanding.

We believe adjusted EBITDA, adjusted net income, and adjusted diluted earnings per share are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, these measures are frequently used by analysts, investors, and other interested parties to evaluate and assess performance.

Adjusted EBITDA, adjusted net income, and adjusted diluted earnings per share are non-GAAP measures and are presented for supplemental purposes only and should not be considered as an alternative or substitute to financial information presented in accordance with GAAP. Adjusted EBITDA, adjusted net income, and

------

adjusted diluted earnings per share have certain limitations in that they do not include the impact of certain expenses that are reflected in our condensed consolidated statements of operations and comprehensive income (loss) that are necessary to run our business. Other companies, including those in our industry, may not use these measures and may calculate them differently than those presented, limiting the usefulness as a comparative measure.

The following table reconciles net income (loss) to Adjusted EBITDA:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** |
| | 2025 | 2024 | 2025 | 2024 |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Net income (loss)(a) | $1525 | $(1371) | $4300 | $(18628) |
| Interest expense(a) | 5011 | 5187 | 14619 | 16516 |
| Interest income(a) | (1270) | (2609) | (4155) | (7669) |
| (Benefit from) Provision for income taxes(a) | (1792) | (290) | 6226 | (736) |
| Intangible asset amortization and fixed assets depreciation(a) | 18626 | 16792 | 56058 | 49817 |
| Currency (gain) loss(a) | (534) | 1546 | (1173) | 2526 |
| Equity-based compensation expense(b) | 9574 | 8187 | 24889 | 27043 |
| Change in fair value of contingent consideration(d) | 2689 | 2431 | (3212) | 8092 |
| Acquisition-related expenses(e) | 1104 | 1364 | 2408 | 4151 |
| Transaction-related expenses (f) |  | (128) |  | 2625 |
| Severance expense (g) |  |  |  | 183 |
| Reorganization expense(h) | 38 | 1730 | 1123 | 3944 |
| Loss on disposal of fixed assets(i) | 31 |  | 36 | 13 |
| Executive recruiting expense(j) |  | 222 | 661 | 645 |
| Litigation and settlement expense(k) | 246 |  | 246 |  |
| Adjusted EBITDA | $35248 | $33061 | $102026 | $88522 |

---

------

The following table reconciles net income (loss) to adjusted net income:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Net income (loss) (a) | $1525 | $(1371) | $4300 | $(18628) |
| Currency (gain) loss(a) | (534) | 1546 | (1173) | 2526 |
| Equity-based compensation expense(b) | 9574 | 8187 | 24889 | 27043 |
| Amortization of acquisition-related intangible assets(c) | 14050 | 13351 | 42120 | 40041 |
| Change in fair value of contingent consideration(d) | 2689 | 2431 | (3212) | 8092 |
| Acquisition-related expenses(e) | 1104 | 1364 | 2408 | 4151 |
| Transaction-related expenses (f) |  | (128) |  | 2625 |
| Severance expense (g) |  |  |  | 183 |
| Reorganization expense(h) | 38 | 1730 | 1123 | 3944 |
| Loss on disposal of fixed assets(i) | 31 |  | 36 | 13 |
| Executive recruiting expense(j) |  | 222 | 661 | 645 |
| Litigation and settlement expense(k) | 246 |  | 246 |  |
| Income tax expense impact of adjustments(l) | (6477) | (7079) | (15348) | (22442) |
| Adjusted net income | $22246 | $20253 | $56050 | $48193 |

---

------

The following table reconciles diluted earnings per share to adjusted diluted earnings per share:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Diluted earnings per share(a) | 0.01 | (0.01) | 0.03 | (0.12) |
| Currency (gain) loss(a) |  | 0.01 |  | 0.02 |
| Equity-based compensation expense(b) | 0.06 | 0.05 | 0.16 | 0.17 |
| Amortization of acquisition-related intangible assets(c) | 0.08 | 0.08 | 0.26 | 0.25 |
| Change in fair value of contingent consideration(d) | 0.02 | 0.02 | (0.02) | 0.05 |
| Acquisition-related expenses(e) | 0.01 | 0.01 | 0.01 | 0.03 |
| Transaction-related expenses (f) |  |  |  | 0.02 |
| Severance expense (g) |  |  |  |  |
| Reorganization expense(h) |  | 0.01 | 0.01 | 0.02 |
| Loss on disposal of fixed assets (i) |  |  |  |  |
| Executive recruiting expense(j) |  |  |  |  |
| Litigation and settlement expense(k) |  |  |  |  |
| Income tax expense impact of adjustments(l) | (0.04) | (0.04) | (0.10) | (0.14) |
| Adjusted diluted earnings per share | $0.14 | $0.13 | $0.35 | $0.30 |
| Basic weighted average common shares outstanding | 160403011 | 160642052 | 160769603 | 160225375 |
| Effect of potentially dilutive shares outstanding (m) | 197559 | 323745 | 494273 | 723301 |
| Adjusted diluted weighted average common shares outstanding | 160600570 | 160965797 | 161263876 | 160948676 |

---

__________________________________

(a)Represents a measure determined under GAAP.

(b)Represents expenses related to equity-based compensation. Equity-based compensation has been, and we expect will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

(c)Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.

(d)Represents expense associated with remeasuring fair value of contingent consideration of business acquisitions.

(e)Represents costs associated with mergers and acquisitions and any retention bonuses pursuant to the acquisitions.

(f)Represents costs associated with our public offerings that are not capitalized, as well as debt issuance costs that are not deferred or treated as a contra-liability directly deducted from the carrying value of the associated debt liability.

------

(g)Represents charges for severance provided to former executives.

(h)Represents expenses related to reorganization, including legal entity reorganization and lease abandonment costs associated with the evaluation of our office space footprint.

(i)Represents the gain or loss related to the disposal of fixed assets.

(j)Represents recruiting and relocation expenses related to hiring senior executives.

(k)Represents expense related to a non-recurring employment litigation and settlement outside the normal course of business.

(l)Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.

(m)Represents potentially dilutive shares that were included from our GAAP diluted weighted average common shares outstanding.

In addition to adjusted EBITDA, adjusted net income, and adjusted diluted earnings per share, management also uses organic revenue, a non-GAAP financial metric, to measure the growth of our existing business operations excluding the impact of acquisitions and divestitures. Our definition of organic revenue may not be comparable to similarly titled measures used by other companies and is not a measure of performance presented in accordance with GAAP.

The table below presents revenue growth from organic operations and acquisitions:

---

| | | |
|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **Growth YTD Q3 2025 vs YTD Q3 2024** |
| | 2025 | % |
| | (in thousands except percentage) | (in thousands except percentage) |
| Total revenues | $315190 | 11% |
| Revenue related to acquisition | (17013) | 6% |
| Organic revenue | $298177 | 5% |

---

**Components of Results of Operations**

**Revenues**

Our business generates revenue from the sales of software products and the delivery of consulting services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Software***. Our software business generates revenues from software licenses, software subscriptions and software maintenance as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Software licenses*: We recognize revenue for software license fees up front, upon delivery of the software license.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Software subscription*: Subscription revenue consists of subscription fees to provide our customers access to and related support for our cloud-based solutions. We recognize subscription fees ratably over the term of the subscription, usually one to three years. Any subscription revenue paid upfront

------

that is not recognized in the current period is included in deferred revenue in our condensed consolidated balance sheet until earned.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Software maintenance*: Software maintenance revenue includes fees for providing updates and technical support for software offerings. Software maintenance revenue is recognized ratably over the contract term, usually one year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Services***. Our services business generates revenues primarily from technology-driven services and professional services, which include software implementation services. Our service arrangements are time and materials, a fixed fee, or prepaid. Revenues are recognized over the time as services are performed for time and materials, and over time by estimating progress to completion for fixed fee and prepaid services.

**Cost of Revenues**

Cost of revenues consists primarily of employee-related expenses, equity-based compensation, the costs of third-party subcontractors, travel costs, distributor fees, amortization of capitalized software, and allocated overhead. We may add or expand computing infrastructure service providers, make additional investments in the availability and security of our solutions, or add resources to support our growth.

**Operating Expenses**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Sales and Marketing***. Sales and marketing expenses consist primarily of employee-related expenses, equity-based compensation, sales commissions, brand development, advertising, travel-related expenses, and industry conferences and events. We plan to continue to invest in sales and marketing to increase penetration of our existing client base and expand to new clients.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***• Research and Development***. R&D expense consist primarily of employee-related expenses, equity-based compensation, third-party consulting, software costs, and tax credits. We plan to continue to invest in our R&D efforts to enhance and scale our software product offerings by development of new features and increased functionality.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***General and Administrative***. General and administrative expenses ("G&A") consist of personnel-related expenses associated with our executive, legal, finance, human resources, information technology, and other administrative functions, including salaries, benefits, bonuses, and equity-based compensation. G&A expenses also include professional fees for external legal, accounting and other consulting services, allocated overhead costs, and other general operating expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Intangible Asset Amortization***. Intangible asset amortization consists primarily of amortization expense related to intangible assets recorded in connection with acquisitions and amortization of capitalized software development costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Depreciation and Amortization Expense***. Depreciation and amortization expenses consist of depreciation of property and equipment and amortization of leasehold improvements.

**Other Expenses**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Interest Expense***. Interest expense consists primarily of interest expense associated with our Credit Agreement, including amortization of debt issuance costs and discounts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Net Other Income (Expense)***. Net other income (expense) consists of miscellaneous non-operating expenses primarily comprised of interest income and foreign exchange transaction gains and losses.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Provision for (Benefit from) Income Taxes***. Provision for (benefit from) income taxes consists of U.S. federal and state income taxes and income taxes in certain foreign jurisdictions in which we conduct business. We expect income tax expense to increase over time as the Company continues to grow more profitable.

**Business Combinations**

Since 2013 and as of September 30, 2025, we have completed 21 acquisitions, of which 14 have included software or technology. Details of acquisitions that have closed since the beginning of fiscal year 2024 are provided below. We continually seek and assess a range of highly focused opportunities in our immediately addressable market and in related adjacent markets, whether through acquisitions, licenses, or partnerships.

***Chemaxon, Kft. ("Chemaxon")***

On October 1, 2024, we completed the acquisition of 100% of the equity of Chemaxon, a software company that develops leading software products for chemical structure drawing, property prediction, search, and analysis, for a total cash consideration of $96.4 million. Based on our purchase price allocation, approximately $36.0 million, $11.0 million, $2.9 million, $0.3 million, and $49.4 million of the purchase price was assigned to developed technology, customer relationships, trademark, non-compete agreement, and goodwill, respectively. The results of Chemaxon have been included in our consolidated results of operations and comprehensive income (loss) since the date of acquisition.

For more information about our acquisitions, see Note 4. "Business Combinations" in the notes to the condensed consolidated financial statements.

**Results of Operations**

We have included the results of operations of acquired companies in our condensed consolidated results of operations from the date of their respective acquisitions, which impacts the comparability of our results of operations when comparing results for the three and nine months ended September 30, 2025 to the three and nine months ended September 30, 2024, respectively.

**Three Months Ended September 30, 2025 Versus Three Months Ended September 30, 2024**

The following table summarizes our unaudited statements of operations data for the three months ended at September 30, 2025 and 2024:

***Revenues***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | (in thousands) | (in thousands) | |
| Software | $43830 | $35912 | 22% |
| Services | 60786 | 58908 | 3% |
| Total revenues | $104616 | $94820 | 10% |

---

------

Total revenues increased $9.8 million, or 10%, to $104.6 million for the three months ended September 30, 2025 as compared to the same period in 2024. The overall revenue growth was primarily driven by growth from a business acquisition, which increased revenue by $5.8 million, as well as increased revenue from our technology-enabled services and software product offerings, driven by strong demand from existing customers, expansion of relationships with existing customers and new customers.

Software revenues increased $7.9 million, or 22%, to $43.8 million for the three months ended September 30, 2025 as compared to the same period in 2024, primarily driven by growth from a business acquisition, which increased revenue by $5.6 million, as well as strong demand within existing customers and expansion of relationships with existing customers.

Services revenues increased $1.9 million, or 3%, to $60.8 million for the three months ended September 30, 2025 as compared to the same period in 2024, primarily attributed to continued growth in technology-enabled services with existing and new customers.

***Cost of Revenues***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Cost of revenues | $39718 | $37189 | 7% |
| % of total revenues | 38% | 39% |  |

---

Cost of revenues increased $2.5 million, or 7%, to $39.7 million for the three months ended September 30, 2025 as compared to the same period in 2024. The increase was primarily due to a $1.2 million increase in intangible assets amortization, a $0.7 million increase in professional and consulting expense, a $0.7 million increase in license cost, and a $0.2 million increase in equipment and software expense, partially offset by a $0.4 million decrease in employee-related costs.

***Sales and Marketing Expenses***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Sales and marketing | $12998 | $11347 | 15% |
| % of total revenues | 12% | 12% |  |

---

Sales and marketing expenses increased by $1.7 million, or 15%, to $13.0 million for the three months ended September 30, 2025 as compared to the same period in 2024. Sales and marketing expenses increased primarily due to a $1.7 million increase in employee-related costs mainly resulting from head count growth driven by acquisitions along with investment to build the commercial organization, and a $0.3 million increase in stock-based compensation costs, partially offset by a $0.2 million decrease in marketing expense and a $0.2 million decrease in commission expense.

------

***Research and Development Expenses***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Research and development | $10266 | $8271 | 24% |
| % of total revenues | 10% | 9% |  |

---

Research and development expenses increased by $2.0 million, or 24%, to $10.3 million for the three months ended September 30, 2025 as compared to the same period in 2024. The increase in research and development expenses was primarily due to a $3.5 million increase in employee-related costs mainly resulting from head count growth associated with investments in software development, including AI integration across our product portfolio, and a $0.2 million increase in professional and consulting expense, partially offset by a $1.2 million increase in capitalized cost in R&D, a $0.2 million decrease in stock-based compensation costs, and a $0.2 million decrease in license cost.

***General and Administrative Expenses***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| General and administrative | $24647 | $22030 | 12% |
| % of total revenues | 24% | 23% |  |

---

General and administrative expenses increased by $2.6 million, or 12%, to $24.6 million for the three months ended September 30, 2025 as compared to the same period in 2024. The increase in general and administrative expenses was primarily due to a $1.3 million increase in stock-based compensation costs, a $0.7 million increase in equipment and software expense, a $0.7 million increase in provision for credit allowance, a $0.5 million increase in miscellaneous operation expenses, a $0.3 million increase in employee-related costs, a $0.3 million reduction related to remeasurement changes in the fair value of contingent consideration, and a $0.2 million increase in public company and transaction expenses, partially offset by a $1.2 million decrease in lease abandonment expense, and a $0.2 million decrease in executive recruiting expense.

***Depreciation and Amortization***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Depreciation and amortization | $13982 | $13389 | 4% |
| % of total revenues | 13% | 14% |  |

---

Amortization and depreciation expense increased by $0.6 million, or 4%, to $14.0 million for the three months ended September 30, 2025 as compared to the same period in 2024. The increase in depreciation and amortization expense was primarily due to a $0.7 million net increase in intangible assets amortization, which included a $1.3 million increase in amortization of capitalized software, partially offset by a $0.5 million decrease in amortization of acquired intangible assets. In addition, depreciation expense for fixed assets

------

decreased $0.1 million, primarily due to a $0.1 million decrease in depreciation of computer equipment and furniture and fixture.

***Interest Expense***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Interest expense | $5011 | $5187 | (3)% |
| % of total revenues | 5% | 5% |  |

---

Interest expense decreased by $0.2 million, or 3%, to $5.0 million for the three months ended September 30, 2025, as compared to the same period in 2024. The change in interest expense was primarily due to a $0.8 million decrease in interest from our floating rate term loan debt, primarily due to a decline in market interest rates and a reduced base margin rate resulting from the refinancing of the term loan, and a $0.1 million decrease in other various items, partially offset by a $0.8 million decrease in gain from our interest swap hedge activities.

***Net Other Income***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Net other (income) expense | $(1739) | $(932) | 87% |
| % of total revenues | (2)% | (1)% |  |

---

Net other income increased by $0.8 million to $1.7 million for the three months ended September 30, 2025 as compared to the same period in 2024. The increase in net other income was primarily due to a $2.7 million increase in gain from remeasurement related to the fluctuation of the foreign currency rate, partially offset by a $1.3 million decrease in interest income, and a $0.6 million increase in other expense.

***Benefits from Income Taxes***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Benefits from income taxes | $(1792) | $(290) | 518% |
| Effective income tax rate | 671% | 17% |  |

---

Our income tax benefit was $1.8 million, resulting in an effective income tax rate of 671% for the three months ended September 30, 2025 as compared to an income tax benefit of $0.3 million, or an effective income tax rate of 17%, for the same period in 2024. Our income tax benefit for the three months ended September 30, 2025 and 2024 was primarily due to the tax effects of U.S. pre-tax income, the relative mix of domestic and international earnings, the impact of non-deductible items, adjustments to the valuation allowances, the effects of tax elections made for U.K. earnings, and discrete tax items.

------

***Net Income (Loss)***

---

| | | | |
|:---|:---|:---|:---|
| | **THREE MONTHS ENDED SEPTEMBER 30,** | **THREE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Net income (loss) | $1525 | $(1371) | 211% |

---

Net income was $1.5 million representing a $2.9 million increase in net income for the three months ended September 30, 2025 as compared to a net loss of $1.4 million for the same period of 2024. The increase in net income was primarily due to a $9.8 million increase in revenue, a $1.5 million increase in tax benefit, and a $1.0 million decrease in total other net expense, partially offset by a $6.9 million increase in operating expenses, and a $2.5 million increase in cost of revenue.

**Nine Months Ended September 30, 2025 Versus Nine Months Ended September 30, 2024**

The following table summarizes our unaudited statements of operations data for the nine months ended September 30, 2025 and 2024:

***Revenues***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Software | $136894 | $113426 | 21% |
| Services | 178296 | 171361 | 4% |
| Total revenues | $315190 | $284787 | 11% |

---

Total revenues increased $30.4 million, or 11%, to $315.2 million for the nine months ended September 30, 2025 as compared to the same period in 2024. The overall revenue growth was primarily driven by growth from a business acquisition, which increased revenue by $17.0 million, as well as increased revenue from our technology-enabled services and software product offerings, driven by strong demand from existing customers, expansion of relationships with existing customers and new customers.

Software revenues increased $23.5 million, or 21%, to $136.9 million for the nine months ended September 30, 2025 as compared to the same period in 2024, primarily driven by growth from a business acquisition, which increased revenue by $16.2 million, as well as strong demand within existing customers, and expansion of relationships with existing customers.

Services revenues increased $6.9 million, or 4%, to $178.3 million for the nine months ended September 30, 2025 as compared to the same period in 2024, primarily attributed to continued growth in technology-enabled services with existing and new customers.

------

***Cost of Revenues***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Cost of revenues | $121955 | $116253 | 5% |
| % of total revenues | 39% | 41% |  |

---

Cost of revenues increased $5.7 million, or 5%, to $122.0 million for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase was primarily due to a $3.7 million increase in intangible assets amortization, a $2.4 million increase in license and service cost, a $1.5 million increase in professional and consulting expense, a $0.5 million increase related to executive recruiting expenses, and a $0.5 million increase in equipment and software expense, partially offset by a $1.7 million decrease in employee related costs and a $1.2 million decrease in stock-based compensation costs.

***Sales and Marketing Expenses***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Sales and marketing | $39704 | $34247 | 16% |
| % of total revenues | 13% | 12% |  |

---

Sales and marketing expenses increased by $5.5 million, or 16%, to $39.7 million for the nine months ended September 30, 2025 as compared to the same period in 2024. Sales and marketing expenses increased primarily due to a $5.1 million increase in employee-related costs mainly resulting from head count growth driven by investment to build the commercial organization along with acquisitions, a $0.6 million increase in stock-based compensation costs, and a $0.3 million increase in equipment and software expense, partially offset by a $0.2 million decrease in travel related expenses, a $0.2 million decrease in professional and consulting expense, and a $0.1 million decrease in marketing expense.

***Research and Development Expenses***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Research and development | $29760 | $29333 | 1% |
| % of total revenues | 9% | 10% |  |

---

Research and development expenses increased by $0.4 million, or 1%, to $29.8 million for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase in research and development expenses was primarily due to a $7.6 million increase in employee-related costs, mainly resulting from head count growth associated with investments in software development, including AI integration across our product portfolio, partially offset by a $4.8 million increase in capitalized cost in R&D, reflecting strategic investments, a $1.6 million decrease in stock-based compensation costs, a $0.6 million decrease in licensing cost, and a $0.1 million decrease in professional and consulting expense.

------

***General and Administrative Expenses***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| General and administrative | $61487 | $73080 | (16)% |
| % of total revenues | 20% | 26% |  |

---

General and administrative expenses decreased by $11.6 million, or 16%, to $61.5 million for the nine months ended September 30, 2025 as compared to the same period in 2024. The decrease in general and administrative expenses was primarily due to a $11.3 million decrease related to remeasurement changes in the fair value of contingent consideration, a $2.4 million decrease in transaction costs primarily due to significant refinancing expenses for a term loan and revolving line of credit incurred in the same period of the prior year, a $2.0 million decrease in lease abandonment expense, a $0.8 million decrease in merger and acquisition cost, and a $0.5 million decrease in executive recruiting expense, partially offset by a $2.3 million increase in professional and consulting expense, a $1.6 million increase in equipment and software expense, a $0.6 million increase in miscellaneous operation expenses, a $0.4 million increase in facility and lease related expenses, a $0.3 million increase in public company expense, a $0.3 million increase in provision for credit allowance, and a $0.3 million increase in travel related expense.

***Depreciation and Amortization***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Depreciation and amortization | $42104 | $39608 | 6% |
| % of total revenues | 13% | 14% |  |

---

Amortization and depreciation expense increased by $2.5 million, or 6%, to $42.1 million for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase in depreciation and amortization expense was primarily due to a net $2.7 million increase in intangible assets amortization, which included a $4.4 million increase in amortization of capitalized software, partially offset by a $1.7 million decrease in amortization of acquired intangible assets. In addition, depreciation expense for fixed assets decreased $0.2 million, primarily due to a $0.2 million decrease in depreciation of furniture and fixture, as well as leasehold improvements.

***Interest Expense***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Interest expense | $14619 | $16516 | (11)% |
| % of total revenues | 5% | 6% |  |

---

Interest expense decreased by $1.9 million, or 11%, to $14.6 million for the nine months ended September 30, 2025, as compared to the same period in 2024. The change in interest expense was primarily due to a $3.4 million decrease in interest from our floating rate term loan debt, primarily due to a decline in market interest

------

rates and a reduced base margin rate resulting from the refinancing of the term loan, and a $0.5 million decrease related to the amortization of debt issuance cost, partially offset by a $1.9 million decrease in gain from our interest swap hedge activities.

***Net Other Income***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Net other (income) expense | $(4965) | $(4886) | 2% |
| % of total revenues | (2)% | (2)% |  |

---

Net other income increased by $0.1 million to $5.0 million for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase in net other income was primarily due to a $4.3 million increase in gain from remeasurement related to the fluctuation of the foreign currency rate, partially offset by a $3.5 million decrease in interest income and a $0.7 million increase in other expense.

***Provision (Benefit) for Income Taxes***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Provision (Benefit) for income taxes | $6226 | $(736) | (946)% |
| Effective income tax rate | 59% | 4% |  |

---

Our income tax expense was $6.2 million, resulting in an effective income tax rate of 59% for the nine months ended September 30, 2025, as compared to an income tax benefit of $0.7 million, or an effective income tax rate of 4%, for the same period in 2024. Our income tax expense for the nine months ended September 30, 2025 and 2024 was primarily due to the tax effects of U.S. pre-tax income, the relative mix of domestic and international earnings, the impact of non-deductible items, adjustments to the valuation allowances, the effects of tax elections made for U.K. earnings, and discrete tax items.

***Net Income (Loss)***

---

| | | | |
|:---|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** | **CHANGE** |
| | **2025** | **2024** | $**%** |
| | **(in thousands)** | **(in thousands)** | |
| Net income (loss) | $4300 | $(18628) | 123% |

---

Net income was $4.3 million representing a $22.9 million increase in net income for the nine months ended September 30, 2025 as compared to a net loss of $18.6 million for the same period of 2024. The increase in net income was primarily due to a $30.4 million increase in revenue, a $3.2 million decrease in operating expenses, a $1.9 million decrease in interest expense, partially offset by an $7.0 million increase in tax expense and a $5.7 million increase in cost of revenue.

------

**Liquidity and Capital Resources**

We have consistently generated positive cash flow from operations, providing $67.5 million and $31.1 million as a source of funds for the nine months ended September 30, 2025 and 2024, respectively. Our additional liquidity comes from several sources: maintaining adequate balances of cash and cash equivalents, issuing common stock, and accessing credit facilities and revolving lines of credit. The following table provides a summary of the major sources of liquidity for the nine- and 12-month periods ended at September 30, 2025 and December 31, 2024 and as of September 30, 2025 and December 31, 2024.

---

| | | |
|:---|:---|:---|
| | **SEPTEMBER 30, 2025** | **DECEMBER 31,<br>2024** |
| | **(dollars in thousands)** | **(dollars in thousands)** |
| Net cash from operating activities<sup>(a)</sup> | 67508 | 80466 |
| Cash and cash equivalents<sup>(b)</sup> | 172711 | 179183 |
| Term loan credit facilities | 296250 | 298500 |
| Revolving line of credit | 100000 | 100000 |

---

___________________________________

(a) &nbsp;&nbsp;&nbsp;&nbsp;Net cash from operating activities for nine months ended September 30, 2025 and twelve months ended December 31, 2024.

(b)&nbsp;&nbsp;&nbsp;&nbsp;Cash balances as of September 30, 2025 and December 31, 2024 included $71.7 million and $45.8 million in cash and cash &nbsp;&nbsp;&nbsp;&nbsp;equivalents, respectively, held outside of the United States.

On April 11, 2025, our Board of Directors approved a stock repurchase program authorizing the Company to repurchase up to $100.0 million of its common stock. During the nine months ended September 30, 2025, we repurchased 3,023,677 shares of our common stock for a total purchase price and fees of $38.7 million. As of September 30, 2025, approximately $61.3 million net after fees, remained available under the stock repurchase program.

Our other material cash requirements from known contractual obligations are principal and interest payments on long term debt. We also have future cash obligations of $16.2 million for lease contracts, which have remaining terms of one to nine years.

The principal amount of long-term debt outstanding as of September 30, 2025 matures in the following years:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Remainder of 2025** | **2026** | **2027** | **2028** | **2029** | **Thereafter** | **TOTAL** |
| | (in thousands) | (in thousands) | (in thousands) | (in thousands) | (in thousands) | (in thousands) | (in thousands) |
| Maturities | $750 | $3000 | $3000 | $3000 | $3000 | $283500 | $296250 |

---

We assess our liquidity in terms of our ability to generate adequate amounts of cash to meet current and future needs. We believe our existing sources of liquidity will be sufficient to meet our working capital, capital expenditures, and contractual obligations for the foreseeable future. Our expected primary uses on a short-term and long-term basis are for repayment of debt, interest payments, working capital, capital expenditures, geographic or service offering expansion, acquisitions, investments, and other general corporate purposes. We believe we will meet short-term and long-term expected future cash requirements and obligations through a combination of cash flows from operating activities, available cash balances, and potential future equity or debt transactions.

Our future capital requirements, however, will depend on many factors, including funding for potential acquisitions, investments, and other growth and strategic opportunities, which could increase our cash requirements. While we believe we have, and will be able to generate, sufficient liquidity to fund our operations

------

for the foreseeable future, our sources of liquidity could be affected by factors described under "Risk Factors" in our 2024 Annual Report.

**Cash Flows**

The following table presents a summary of our cash flows for the periods shown:

---

| | | |
|:---|:---|:---|
| | **NINE MONTHS ENDED SEPTEMBER 30,** | **NINE MONTHS ENDED SEPTEMBER 30,** |
| | **2025** | **2024** |
| | **(in thousands)** | **(in thousands)** |
| Net cash provided by operating activities | $67508 | $31097 |
| Net cash used in investing activities | (19527) | (15205) |
| Net cash used in financing activities | (59173) | (19707) |
| Effect of foreign exchange rate changes on cash and cash equivalents, and restricted cash | 4720 | 1887 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash and cash equivalents, and restricted cash | $(6472) | $(1928) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $10456 | $11171 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes | $8769 | $11630 |

---

***Operating Activities***

Our cash flows from operating activities primarily include net income adjusted for (i) non-cash items included in net income, such as provisions (recoveries) for credit losses, depreciation and amortization, stock-based compensation, deferred taxes, and other non-cash items and (ii) changes in the balances of operating assets and liabilities. Net cash provided by operating activities in the first nine months of 2025 was $67.5 million, compared to $31.1 million in the same period of 2024. The $36.4 million increase in cash from operating activities was primarily driven by an increase in cash-adjusted net income, a decrease in accounts receivable, a decrease in cash outflow in accrued expenses and other liabilities, and lower cash outflows related to prepaid and other assets, partially offset by lower cash inflows from deferred revenues.

***Investing Activities***

Net cash used in investing activities in the first nine months of 2025 was $19.5 million, an increase of $4.3 million, compared to $15.2 million in the same period of 2024. The change in investing activities was primarily due to a $4.8 million increase in cash utilized in capitalized software development costs to support our growth and a $0.5 million decrease in cash outflow for capital expenditure.

***Financing Activities***

Net cash used by financing activities in the first nine months of 2025 was $59.2 million, compared to $19.7 million in the same period of 2024. The $39.5 million increase in cash outflow in financing activities was primarily due to a $38.7 million increase in cash used in connection with repurchasing the Company's common stock, a $6.3 million decrease in cash inflow from debt refinancing activities, and a $0.7 million increase in prepayments on term loan debt, partially offset by a $3.1 million decrease in cash payments associated with share awards vested and withheld for payroll tax, a $1.9 million decrease in cash payments for contingent consideration related to a business acquisition, and a $1.2 million decrease in payment for debt refinancing fees.

------

**Indebtedness**

We have been a party to a Credit Agreement since August 2017 that provides for a senior secured term loan and commitments under a revolving credit facility (as amended, the "Credit Agreement"). On June 26, 2024, we entered into the Fifth Amendment to the Credit Agreement (the "Amendment"), which primarily (1) amended the principal amount of the term loan to $300.0 million and the maturity date to June 26, 2031; and (2) extended the termination date associated with the $100.0 million revolving credit commitment to June 26, 2029. The term loan under this Amendment has substantially the same terms as the existing term loans and revolving credit commitments.

Borrowings under the Credit Agreement bear interest at a rate per annum equal to, at the election of the Borrowers, either (i) the Term SOFR rate, with a floor of 0.00% plus an applicable margin rate of 3.00% for the Term Loans and between 3.50% and 2.75% for loans under the Revolving Facility, depending on the applicable first lien leverage ratio or (ii) an Alternate Base Rate ("ABR"), with a floor of 1.00%, plus an applicable margin rate of 2.00% for the Term Loans or between 2.50% and 1.75% for loans under the Revolving Facility, depending on the applicable first lien leverage ratio. The ABR is determined as the greatest of (a) the prime rate, (b) the federal funds effective rate, plus 0.50% and (iii) the Term SOFR rate plus 1.00%. Additionally, we are obligated to pay a commitment fee on the unused amount and other customary fees.

All obligations under the Credit Agreement, and the guarantees of those obligations, are secured on a first lien basis, subject to certain exceptions, by substantially all of our assets and the assets of the other guarantors. As of September 30, 2025, we were in compliance with the covenants of the Credit Agreement. Additionally, in October 2025, the Company entered into a Sixth Amendment to its Credit Agreement, which, among other changes, reduces the applicable rate for existing term loans. For further details on the Sixth Amendment, see Note 14, "Subsequent Event".

As of September 30, 2025, we had $296.3 million of outstanding borrowings on the term loan, and $100.0 million of availability under the revolving credit facility under the Credit Agreement.

**Contractual Obligations and Commercial Commitments**

There have been no material changes to our contractual obligations during the nine months ended September 30, 2025 from those disclosed in our 2024 Annual Report, except for payments made in the ordinary course of business.

**Income Taxes**

We recorded income tax expense of $6.2 million for the nine months ended September 30, 2025 and income tax benefit $0.7 million for the nine months ended September 30, 2024.

As of September 30, 2025, we had federal and state NOLs of approximately $6.2 million and $4.9 million, respectively, which are available to reduce future taxable income and expire between 2035 and 2036 and 2029 and 2040, respectively. We had federal R&D tax credit carryforwards of approximately $0.3 million to offset future income taxes, which expire between 2027 and 2048. We also had foreign tax credits of approximately $11 million, which will start to expire in 2027. These carryforwards that may be utilized in a future period may be subject to limitations based upon changes in the ownership of our stock in a future period. Additionally, we carried forward foreign NOLs of approximately $78.6 million which will start to expire in 2025, foreign research and development credits of $0.3 million which expire in 2029, and Canadian investment tax credits of approximately $3.9 million which expire between 2032 and 2042. Our carryforwards are subject to review and possible adjustment by the appropriate taxing authorities.

------

As required by Accounting Standards Codification (''ASC'') Topic 740, Income Taxes, our management has evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets, which are composed principally of NOL carryforwards, Section 174 carryforwards, investment tax credit carryforward, and foreign tax credit carryforwards. Management has determined that it is more likely than not that we will not realize the benefits of foreign tax credit carryforwards. At the foreign subsidiaries, management has determined that it is more likely than not that we will not realize the benefits of certain NOL carryforwards. As a result, a valuation allowance of $24 million is recorded at December 31, 2024. As of September 30, 2025, the valuation allowance remained unchanged from December 31, 2024.

On July 4, 2025, the United States enacted the One Big Beautiful Bill Act (the "OBBBA"), which includes changes to U.S. tax law such as significant amendments to the U.S. federal income tax code. Key provisions include the permanent reinstatement of immediate expensing for domestic research expenditures, the restoration of full expensing for qualified machinery, equipment and other short-lived assets, and several modifications to existing international tax provisions. These provisions were enacted subsequent to the end of third quarter of 2025 and therefore are not reflected in the accompanying condensed consolidated financial statements. The Company is in the process of evaluating the impact of the OBBBA.

**Off-Balance Sheet Arrangements**

During the periods presented, we did not have, and currently do not have, any off-balance sheet arrangements, as defined under the rules and regulations of the SEC, that have, or are reasonably likely to have, a material effect on our current or future financial condition, results of operations, liquidity, capital expenditures, or capital resources.

**Critical Accounting Estimates**

Our accounting policies are more fully described in Note 2 "Summary of Significant Accounting Policies," in our audited consolidated financial statements included in our 2024 Annual Report. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We monitor estimates and assumptions on a continuous basis and update these estimates and assumptions as facts and circumstances change and new information is obtained. Actual results could differ materially from those estimates and assumptions. We discussed the accounting policies that we believe are most critical to the portrayal of our results of operations and financial condition and require management's most difficult, subjective, and complex judgments in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," in our 2024 Annual Report. There were no significant changes to our critical accounting estimates during the three months ended September 30, 2025.

**Recently Adopted and Issued Accounting Standards**

We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2."Summary of Significant Accounting Policies" to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report, such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our operations.

------

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

For information regarding our exposure to certain market risks, see "Quantitative and Qualitative Disclosures about Market Risk," in Part II, Item 7A of the Company's 2024 Annual Report. There were no material changes to the Company's market risk exposure during the nine months ended September 30, 2025.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2025.

***Changes in Internal Control over Financial Reporting***

During the three months period ended September 30, 2025, there were no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

------

**PART II — OTHER INFORMATION**

**Item 1. Legal Proceedings**

There have been no material changes to our legal proceedings as previously disclosed in our 2024 Annual Report.

**Item 1A. Risk Factors**

There are no material changes from any of the risk factors previously disclosed in our 2024 Annual Report .

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

The following table illustrates the activities of equity security repurchases during the three months ended at September 30, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Total Number of Shares Purchased (a)(c)** | **Average Price Paid per Share(b)** | **Total Number of Shares Purchased As Part of Publicly Announced Plans or Programs (a)** | **Approximate Dollar Value of Shares That May Yet be Purchased Under the Plans or Programs (a)** |
| 7/1/2025 to 7/31/2025 | 3756 | $11.70 |  | $75.0 million |
| 8/1/2025 to 8/31/2025 | 1510 | 10.05 |  | $75.0 million |
| 9/1/2025 to 9/30/2025 | 1230398 | 11.09 | 1230398 | $61.3 million |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | 1235664 | $11.09 | 1230398 | $61.3 million |

---

__________________________________

a.On April 11, 2025, our Board of Directors approved a stock repurchase program authorizing the Company to repurchase up to $100 million of its common stock. Under this program, the Company may repurchase shares from time to time, depending on market conditions and alternate uses of capital. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions and alternate uses of capital. The share repurchase program may be effected through Rule 10b5-1 plans, open market purchases, each in compliance with Rule 10b-18 under the Exchange Act, or privately negotiated transactions. The program may be suspended or discontinued at any time and does not have an expiration date. During the three months ended September 30, 2025, the Company repurchased 1,230,398 shares of its common stock at an average price of $11.09 per share, as part of the stock repurchase program authorized on April 11, 2025.

b.The Company's net share repurchases are subject to a 1% excise tax under the Inflation Reduction Act. This excise tax is included in the cost of shares repurchased, as reflected in the condense consolidated statement of stockholders' equity. The repurchases above do not include the excise tax.

c.Also includes shares purchased by the Company from employees for the payment of taxes resulting from issuance of common stock upon the vesting of RSUs relating to stock-based compensation plans. Employees tendered 5,266 shares in the third quarter of 2025.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

------

**Item 5. Other Information**

***<u>Trading Plans</u>***

Our directors and officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker to buy or sell our common stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from them.

During the three months ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a Rule 10b5-1 trading plan.

***<u>Adoption of Executive Officer Severance Policy</u>***

The Company has adopted an Executive Officer Severance Policy (the "Severance Policy") with effect as of November 5, 2025 that provides executive officers with varying severance benefits and payments, depending on whether the executive's termination occurs within a two-year period following a change in control (a "CIC protection period") or outside of such a period. To be eligible for severance under the Severance Policy, the executive's employment must have been terminated by the Company without cause or terminated by the executive for good reason.

For executives other than the CEO, the severance benefits include 1-times base salary (or 1-times the sum of base salary plus target bonus if the termination occurs during a CIC protection period), 12 months' subsidized health insurance benefits and a pro-rata annual bonus for the year of termination. For the CEO, the severance benefits include 1-times the sum of base salary plus target bonus (or 1.5-times the sum of base salary plus target bonus if the termination occurs during a CIC protection period), 12 months' subsidized health insurance benefits (or 18 months' subsidized health insurance benefits if the termination occurs during a CIC protection period) and a pro-rata annual bonus for the year of termination. All severance payments and benefits are contingent upon the executive's timely execution and non-revocation of a customary release of claims in favor of the Company and its affiliates, and any severance amounts payable to a covered executive under a separate employment agreement, plan or arrangement will be offset against the severance benefits payable under the Severance Policy.

**Item 6. Exhibits**

See Exhibit Index.

------

**EXHIBIT INDEX**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit<br>Number** | **Exhibit Title** | **Form** | **File No.** | **Exhibit** | **Filing Date** |
| 2.1 | <u>[Agreement and Plan of Merger dated as of August 2, 2021, by and among Certara, Inc., Puma Merger Sub, LLC and Shareholder Representative Services LLC, as the Equityholder Representative thereunder](https://www.sec.gov/Archives/edgar/data/1827090/000110465921100776/tm2123444d2_ex2-1.htm)</u> | 8 - K | 001-39799 | 2.1 | 8/05/2021 |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation of Certara, Inc.](https://www.sec.gov/Archives/edgar/data/1827090/000110465920135789/tm2030105d18_ex4-1.htm)</u> | S-8 | 333-251368 | 4.1 | 12/15/2020 |
| 3.2 | <u>[Certificate of Correction to Amended and Restated Certificate of Incorporation of Certara, Inc.](https://www.sec.gov/Archives/edgar/data/1827090/000182709025000014/exhibit32certificateofcorr.htm)</u> | 10-K | 001-39799 | 3.2 | 2/26/2025 |
| 3.3 | <u>[Second Amended and Restated Bylaws of Certara, Inc.](https://www.sec.gov/Archives/edgar/data/1827090/000182709025000036/exhibit33-secondamendedand.htm)</u> | 10-Q | 001-39799 | 3.3 | 8/6/2025 |
| 31.1 | <u>[Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](cert-20250930xex311.htm)</u> |  |  |  |  |
| 31.2 | <u>[Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](cert-20250930xex312.htm)</u> |  |  |  |  |
| 32.1+ | <u>[Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+](cert-20250930xex321.htm)</u> |  |  |  |  |
| 32.2+ | <u>[Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+](cert-20250930xex322.htm)</u> |  |  |  |  |
| 101.INS | XBRL Instance Document –the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |  |  |  |  |
| 101.SCH | XBRL Taxonomy Extension Schema Document |  |  |  |  |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |  |  |  |  |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |  |  |  |  |

---

___________________________________

+ This certification is deemed not filed for purpose of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filings under the Securities Act or the Exchange Act.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **CERTARA, INC.** | **CERTARA, INC.** |
| Date: November 6, 2025 | By: | /s/ William F. Feehery |
|  | Name: | William F. Feehery |
|  | Title: | Chief Executive Officer<br>(Principal Executive Officer) |
| Date: November 6, 2025 | By: | /s/ John E. Gallagher III |
|  | Name: | John E. Gallagher III |
|  | Title: | Chief Financial Officer<br>(Principal Financial Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

RULE 13a-14(a) CERTIFICATION

CERTARA, INC.

CERTIFICATION OF CHIEF EXECUTIVE OFFICER (Principal Executive Officer)

I, William F. Feehery, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Certara, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: November 6, 2025 | /s/ William F. Feehery |
| | William F. Feehery |
| | Chief Executive Officer |
| | (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

RULE 13a-14(a) CERTIFICATION

CERTARA, INC.

CERTIFICATION OF CHIEF FINANCIAL OFFICER (Principal Financial Officer)

I, John Gallagher, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Certara, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: November 6, 2025 | /s/ John E. Gallagher III |
| | John E. Gallagher III |
| | Chief Financial Officer |
| | (Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**STATEMENT PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS REQUIRED BY**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Certara, Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, the undersigned, hereby certify that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| November 6, 2025 | */s/ William Feehery* |
| | William Feehery |
| | Chief Executive Officer |
| | (Principal Executive Officer) |

---

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

## Exhibit 32.2

**Exhibit 32.2**

**STATEMENT PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS REQUIRED BY**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Certara, Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, the undersigned, hereby certify that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| November 6, 2025 | */s/ John E. Gallagher III* |
| | John E. Gallagher III |
| | Chief Financial Officer |
| | (Principal Financial Officer) |

---

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

<br>